<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological interventions for those who have sexually offended or are at risk of offending - Khan, O - 2015 | Cochrane Library</title> <meta content="Pharmacological interventions for those who have sexually offended or are at risk of offending - Khan, O - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007989.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological interventions for those who have sexually offended or are at risk of offending - Khan, O - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007989.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007989.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological interventions for those who have sexually offended or are at risk of offending" name="citation_title"/> <meta content="Omer Khan" name="citation_author"/> <meta content="The Priory Group" name="citation_author_institution"/> <meta content="omerkhan@priorygroup.com" name="citation_author_email"/> <meta content="Michael Ferriter" name="citation_author"/> <meta content="Nottinghamshire Healthcare NHS Trust" name="citation_author_institution"/> <meta content="Nick Huband" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Melanie J Powney" name="citation_author"/> <meta content="The University of Manchester" name="citation_author_institution"/> <meta content="Jane A Dennis" name="citation_author"/> <meta content="Queen's University Belfast" name="citation_author_institution"/> <meta content="Conor Duggan" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD007989.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/02/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007989.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007989.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007989.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Androgen Antagonists [adverse effects, *therapeutic use]; Antipsychotic Agents [adverse effects, *therapeutic use]; Child Abuse, Sexual [*prevention &amp; control]; Desensitization, Psychologic [methods]; Exhibitionism [drug therapy, prevention &amp; control]; Libido [*drug effects]; Randomized Controlled Trials as Topic; Rape [prevention &amp; control]; Recurrence; Sex Offenses [*prevention &amp; control, psychology]; Sexual Behavior [*drug effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007989.pub2&amp;doi=10.1002/14651858.CD007989.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="tIsQXAzh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007989\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007989\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007989\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007989\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","pt","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007989.pub2",title:"Pharmacological interventions for those who have sexually offended or are at risk of offending",firstPublishedDate:"Feb 18, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Developmental, Psychosocial and Learning Problems Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tIsQXAzh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007989.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007989.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007989.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007989.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007989.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007989.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007989.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007989.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007989.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007989.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007989.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007989.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007989.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007989.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>13130 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007989.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/full#CD007989-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/full#CD007989-sec-0168"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/full#CD007989-sec-0029"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/full#CD007989-sec-0039"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/full#CD007989-sec-0040"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/full#CD007989-sec-0074"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/full#CD007989-sec-0158"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007989.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/appendices#CD007989-sec-0172"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007989.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological interventions for those who have sexually offended or are at risk of offending </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/information#CD007989-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Omer Khan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/information#CD007989-cr-0003">Michael Ferriter</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/information#CD007989-cr-0004">Nick Huband</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/information#CD007989-cr-0005">Melanie J Powney</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/information#CD007989-cr-0006">Jane A Dennis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007989.pub2/information#CD007989-cr-0007">Conor Duggan</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007989.pub2/information/en#CD007989-sec-0182">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 February 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007989.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007989.pub2">https://doi.org/10.1002/14651858.CD007989.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007989-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007989-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007989-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007989-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007989-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD007989-abs-0002">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007989-abs-0001" lang="en"> <section id="CD007989-sec-0001"> <h3 class="title" id="CD007989-sec-0001">Background</h3> <p>Sexual offending is a serious social problem, a public health issue, and a major challenge for social policy. Victim surveys indicate high incidence and prevalence levels and it is accepted that there is a high proportion of hidden sexual victimisation. Surveys report high levels of psychiatric morbidity in survivors of sexual offences. </p> <p>Biological treatments of sex offenders include antilibidinal medication, comprising hormonal drugs that have a testosterone‐suppressing effect, and non‐hormonal drugs that affect libido through other mechanisms. The three main classes of testosterone‐suppressing drugs in current use are progestogens, antiandrogens, and gonadotropin‐releasing hormone (GnRH) analogues. Medications that affect libido through other means include antipsychotics and serotonergic antidepressants (SSRIs). </p> </section> <section id="CD007989-sec-0002"> <h3 class="title" id="CD007989-sec-0002">Objectives</h3> <p>To evaluate the effects of pharmacological interventions on target sexual behaviour for people who have been convicted or are at risk of sexual offending. </p> </section> <section id="CD007989-sec-0003"> <h3 class="title" id="CD007989-sec-0003">Search methods</h3> <p>We searched CENTRAL (2014, Issue 7), Ovid MEDLINE, EMBASE, and 15 other databases in July 2014. We also searched two trials registers and requested details of unidentified, unpublished, or ongoing studies from investigators and other experts. </p> </section> <section id="CD007989-sec-0004"> <h3 class="title" id="CD007989-sec-0004">Selection criteria</h3> <p>Prospective controlled trials of antilibidinal medications taken by individuals for the purpose of preventing sexual offences, where the comparator group received a placebo, no treatment, or 'standard care', including psychological treatment. </p> </section> <section id="CD007989-sec-0005"> <h3 class="title" id="CD007989-sec-0005">Data collection and analysis</h3> <p>Pairs of authors, working independently, selected studies, extracted data, and assessed the risk of bias of included studies. We contacted study authors for additional information, including details of methods and outcome data. </p> </section> <section id="CD007989-sec-0006"> <h3 class="title" id="CD007989-sec-0006">Main results</h3> <p>We included seven studies with a total of 138 participants, with data available for 123. Sample sizes ranged from 9 to 37. Judgements for categories of risk of bias varied: concerns were greatest regarding allocation concealment, blinding of outcome assessors, and incomplete outcome data (dropout rates in the five community‐based studies ranged from 3% to 54% and results were usually analysed on a per protocol basis). </p> <p>Participant characteristics in the seven studies were heterogeneous, but the vast majority had convictions for sexual offences, ranging from exhibitionism to rape and child molestation. </p> <p>Six studies examined the effectiveness of three testosterone‐suppressing drugs: cyproterone acetate (CPA), ethinyl oestradiol (EO), and medroxyprogesterone acetate (MPA); a seventh evaluated two antipsychotics (benperidol and chlorpromazine). Five studies were placebo‐controlled; in two, MPA was administered as an adjunctive treatment to a psychological therapy (assertiveness training or imaginal desensitisation). Meta‐analysis was not possible due to heterogeneity of interventions, comparators, study designs, and other issues. The quality of the evidence overall was poor. In addition to methodological issues, much evidence was indirect. </p> <p><i>Primary outcome: recividism.</i> Two studies reported recidivism rates formally. One trial of intramuscular MPA plus imaginal desensitisation (ID) found no reports of recividism at two‐year follow‐up for the intervention group (n = 10 versus one relapse within the group treated by ID alone). A three‐armed trial of oral MPA, alone or in combination with psychological treatment, reported a 20% rate of recidivism amongst those in the combined treatment arm (n = 15) and 50% of those in the psychological treatment only group (n = 12). Notably, all those in the 'oral MPA only' arm of this study (n = 5) dropped out immediately, despite treatment being court mandated. </p> <p>Two studies did not report recidivism rates as they both took place in one secure psychiatric facility from which no participant was discharged during the study, whilst another three studies did not appear directly to measure recividism but rather abnormal sexual activity alone. </p> <p><i>Secondary outcomes:</i>The included studies report a variety of secondary outcomes. Results suggest that the frequency of self reported deviant sexual fantasies may be reduced by testosterone‐suppressing drugs, but not the deviancy itself (three studies). Where measured, hormonal levels, particularly levels of testosterone, tended to correlate with measures of sexual activity and with anxiety (two studies). One study measured anxiety formally; one study measured anger or aggression. </p> <p><i>Adverse events:</i> Six studies provided information on adverse events. No study tested the effects of testosterone‐suppressing drugs beyond six to eight months and the cross‐over design of some studies may obscure matters (given the 'rebound effect' of some hormonal treatments). Considerable weight gain was reported in two trials of oral MPA and CPA. Side effects of intramuscular MPA led to discontinuation in some participants after three to five injections (the nature of these side effects was not described). Notable increases in depression and excess salivation were reported in one trial of oral MPA. The most severe side effects (extra‐pyramidal movement disorders and drowsiness) were reported in a trial of antipsychotic medication for the 12 participants in the study. No deaths or suicide attempts were reported in any study. The latter is important given the association between antilibidinal hormonal medication and mood changes. </p> </section> <section id="CD007989-sec-0007"> <h3 class="title" id="CD007989-sec-0007">Authors' conclusions</h3> <p>We found only seven small trials (all published more than 20 years ago) that examined the effects of a limited number of drugs. Investigators reported issues around acceptance and adherence to treatment. We found no studies of the newer drugs currently in use, particularly SSRIs or GnRH analogues. Although there were some encouraging findings in this review, their limitations do not allow firm conclusions to be drawn regarding pharmacological intervention as an effective intervention for reducing sexual offending. </p> <p>The tolerability, even of the testosterone‐suppressing drugs, was uncertain given that all studies were small (and therefore underpowered to assess adverse effects) and of limited duration, which is not consistent with current routine clinical practice. Further research is required before it is demonstrated that their administration reduces sexual recidivism and that tolerability is maintained. </p> <p>It is a concern that, despite treatment being mandated in many jurisdictions, evidence for the effectiveness of pharmacological interventions is so sparse and that no RCTs appear to have been published in two decades. New studies are therefore needed and should include trials with larger sample sizes, of longer duration, evaluating newer medications, and with results stratified according to category of sexual offenders. It is important that data are collected on the characteristics of those who refuse and those who drop out, as well as those who complete treatment. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007989-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007989-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD007989-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD007989-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007989-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007989-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD007989-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD007989-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007989-abs-0007">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007989-abs-0005" lang="en"> <h3>Drug treatments for sexual offenders or those at risk of offending</h3> <p><b>Background</b> </p> <p>Victim surveys suggest that sexual offending is common, and survivors experience psychological problems. However, much offending goes undetected because of under‐reporting and failure to successfully prosecute offenders. </p> <p>Medications used to treat sex offenders ('antilibidinal' medications) act by limiting the sexual drive (libido). There are two types, those which work by suppressing testosterone (e.g., progestogens, antiandrogens, and gonadotropin‐releasing hormone (GnRH) analogues), and those that reduce sexual drive by other mechanisms (i.e., antipsychotics and serotonergic antidepressants (SSRIs)). </p> <p>We reviewed evidence for the effectiveness of such drugs in people who were convicted or thought to be at risk of committing sexual offences. </p> <p><b>Search date</b> </p> <p>The evidence in this review is current to July 2014.</p> <p><b>Study characteristics</b> </p> <p>We found seven randomised trials involving 138 participants, which provided data on 123. All were male, aged between 16 and 68 years. Offending ranged from very serious (e.g., rape) to minor criminality (e.g., exhibitionism). Comparators included placebo (five studies), psychological treatment (one study), and a combination of psychological and pharmacological treatment (one study). Five studies took place in the community and two in a secure hospital. Duration varied between three and 13 months. </p> <p>Six studies examined the effectiveness of three testosterone‐suppressing drugs: cyproterone acetate (CPA), ethinyl oestradiol (EO), and medroxyprogesterone acetate (MPA). In two of these studies, MPA was given alongside a psychological therapy (assertiveness training or imaginal desensitisation). The seventh study assessed the effectiveness of two antipsychotics (benperidol and chlorpromazine) versus placebo. Meta‐analysis was not possible due to heterogeneity of interventions, comparator groups, study designs, and other issues. </p> <p><b>Results</b> </p> <p>Two studies reported reoffending rates formally. One trial of intramuscular MPA plus imaginal desensitisation (ID) found no reoffending at two‐year follow‐up for the intervention group (n = 10 versus one relapse within the group treated by ID alone). A three‐armed trial of oral MPA, alone or in combination with psychological treatment, reported a 20% rate of reoffending amongst those in the combined treatment arm (n = 15) and 50% of those in the psychological treatment only group (n = 12). Notably, all those in the 'oral MPA only' arm (n = 5) dropped out immediately, despite treatment being court mandated. Two studies did not report reoffending rates as they both took place in a secure psychiatric facility from which none were discharged. Three community studies did not formally report reoffending at all, focusing largely on 'abnormal sexual activity'. </p> <p><i>Secondary outcomes:</i> Studies reported a variety of secondary outcomes<i>.</i> Results suggested that the frequency of self reported deviant sexual fantasies may be reduced by testosterone‐suppressing drugs, but not the deviancy itself. Where measured, hormonal levels, particularly levels of testosterone, tended to correlate with measures of sexual activity and anxiety. One study measured anxiety formally; one study measured anger/aggression. </p> <p><i>Adverse events:</i> Six studies provided information on adverse events and none tested the effects of testosterone‐suppressing drugs beyond six to eight months. The most severe were reported in a trial of antipsychotic medication. Reported side effects in two trials of oral MPA and CPA included considerable weight gain. Side effects of intramuscular MPA led to discontinuation in some participants. Important increases in depression and excess salivation were reported in one trial of oral MPA. No deaths and no suicide attempts were reported in any study. </p> <p>We conclude that these seven trials (published more than 20 years ago), examining only a limited number of drugs, provide a poor evidence base to guide practice. Not only were the trials small, they were of short duration, included varied participants, and none trialled the newer drugs currently in use, particularly SSRIs or GnRH analogues. The results of this review, therefore, do not allow firm conclusions to be drawn regarding pharmacological interventions as an effective intervention for reducing sexual offending. </p> <p>New studies are needed that address these deficits. Data should also be collected on the characteristics of those who refuse, drop out, and complete treatment. </p> <p><b>Quality of the evidence</b> </p> <p>Overall, the quality of the evidence was poor. We had concerns about: number of participants leaving studies, blinding of those who measured outcomes, ways in which investigators concealed allocation of treatment to those delivering it, and reporting of our primary outcome: reoffending. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007989-sec-0168" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007989-sec-0168"></div> <h3 class="title" id="CD007989-sec-0169">Implications for practice</h3> <section id="CD007989-sec-0169"> <p>As the victim of a sexual offence is likely to suffer considerable harm, an individual convicted of a sexual offence can expect a lengthy custodial sentence. In addition, some states in the USA have now introduced preventative detention for sex offenders who are thought to be at high risk of sexual reoffending in the future. Similarly, amendments to the UK Mental Health Act 1983 have meant that paraphilias are now mental disorders within the meaning of the Act, thereby allowing for their involuntary treatment subject to certain conditions being satisfied. When such 'civil commitment' was challenged in the USA, the Supreme Court made it clear that this can only be legitimate if meaningful treatment is provided (<a href="./references#CD007989-bbs2-0125" title="Justia US SupremeCourt . United States Supreme Court Case: Kansas v. Hendricks ‐ 521 U.S. 346 (1996). http://supreme.justia.com/cases/federal/us/521/346/case.html (accessed 1 September 2012). ">Justia US Supreme Court 1997</a>). </p> <p>In the light of these significant infringements of civil liberty, it is imperative that good quality trial evidence is available if an individual's likelihood of release is to be determined by engaging in an intervention that is deemed to be effective. </p> <p>This review does not provide sufficient evidence for a reduction of sexual recidivism in offenders following pharmacological treatment. While it does identify trends for a reduction of proxy measures of sexual offending with some antiandrogens, these are associated with considerable bias and – because the trials are dated – they inevitably have a focus on medications which may have been superseded in modern practice, and for which adverse events remain of concern. </p> <p>Here, we recognise the frustration of many practising clinicians when faced with treating sexual offenders in their daily practice and expecting that the research community will provide him or her, with some practical and research‐based guidance. Here, the algorithmic treatment regimens of <a href="./references#CD007989-bbs2-0108" title="GrubinD . Medical models and interventions in sexual deviance. In: LawsDR , O'DonohueW editor(s). Sexual Deviancy: Theory, Assessment and Treatment. 2nd Edition. New York: The Guildford Press, 2008. ">Grubin 2008</a> and <a href="./references#CD007989-bbs2-0167" title="ThibautF , De LaBarraF , GordonH , CosynsP , BradfordJM , WFSBP Task Force on Sexual Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias. World Journal of Biological Psychiatry2010;11(4):604‐55. ">Thibaut 2010</a> no doubt have their value, but, from the perspective of evidence‐based practice, these recommendations – however sensible – remain at the lowest level of the evidence hierarchy when not supported by properly conducted randomised controlled trials. </p> </section> <h3 class="title" id="CD007989-sec-0170">Implications for research</h3> <section id="CD007989-sec-0170"> <p>The difficulties in carrying out medication trials for sexual offenders was aptly summarised by a quotation from the oldest trial included in this review (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>) <i>"Not only is it conceivable that a transient placebo effect may follow the use of any preparation, but also one is dealing with sexual offenders in many of whom the main motivation for accepting treatment is their wish to avoid further penalties and in whom the desire to lose the deviant sexual interest is difficult to assess"</i> (p 310). Other investigators identified both acceptance of and compliance with treatment as major obstacles (<a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>; <a href="./references#CD007989-bbs2-0145" title="Nagayama‐HallGC . Sexual offender recidivism revisited: a meta‐analysis of recent treatment studies. Journal of Consulting and Clinical Psychology1995;63(5):802‐9. ">Nagayama‐Hall 1995</a>), together with censure of investigators if a sexual offender in the control group commits a further sexual offence (<a href="./references#CD007989-bbs2-0137" title="MarshallWL , MarshallLE . The utility of the random controlled trial for evaluating sexual offender treatment: the gold standard or an appropriate strategy?. Sexual Abuse: A Journal of Research and Treatment2007;19(2):175‐91. ">Marshall 2007</a>). </p> <p>While all of these are reasonable concerns, they are not unique to the treatment of sexual offenders and other areas of health care facing similar challenges in treatment (e.g., cancer, psychosis) have managed to overcome them. The evidence from this review (and from its companion review into psychological treatments for sexual offenders, <a href="./references#CD007989-bbs2-0088" title="DennisJ , HubandN , KhanO , FerriterM , JonesH , PowneyM , et al. Psychological interventions for adults who have sexually offended or are at risk of offending. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD007507.pub2] ">Dennis 2012</a>) suggests that, whatever advances in treatment are likely to occur, they will be at the margins – i.e., equipoise remains. Consequently, it remains essential to conduct properly designed, large‐scale trials of medications in this area. Given the biological underpinning of sexual activity, one might anticipate that trials of antilibidinal medication would be commonplace; in fact, the reality is the reverse. In this review, for instance, we could only find seven trials of antilibidinal medication that satisfied the Cochrane criteria for acceptability. Given the prevalence of sexual offending, together with its consequences for both the victim and the offender, a failure to provide evidence of an effective intervention is worrying and requires some further analyses. </p> <p>We have reviewed some of the problems in conducting randomised controlled trials for sex offenders in general (<a href="./references#CD007989-bbs2-0091" title="DugganC . The place of evidence in the treatment of sex offenders. Criminal Behaviour and Mental Health2014; Vol. 24, issue 3:153‐62. ">Duggan 2014</a>), and here discuss these in relation to medication. The very point of conducting a randomised trial is to determine (a) if the intervention is effective and (b) that it does no harm. There is the mistaken belief, however, that those randomised to the control condition (particularly if it is a placebo) are likely to be disadvantaged so that were they to reoffend after the study, then the investigator might expect to be criticised; this again can be answered with a challenge to consider ethical equipoise. This may explain why there are (a) so few drug trials in what would otherwise be a profitable area to exploit because of its chronicity and (b) the apparent absence of any trial activity within the past two decades, prior to one ongoing trial in Germany (<a href="./references#CD007989-bbs2-0058" title="BrikenP , BernerW . Double‐blind, controlled, clinical trial planned in Germany to investigate the efficacy of psychotherapy combined with triptorelin in adult male patients with severe pedophilic disorders: presentation of the study protocol. Israel Journal of Psychiatry and Related Sciences2012;49(4):306‐13. ">Briken 2012</a>). </p> <p>Second, drug trials are generally of short duration and, since we know that sexual recidivism may occur after several years of follow‐up, does this mean that the treatment needs to be life‐long to maintain a reduction in sexual offending? Currently, given the extant knowledge, the answer to this question can only be gleaned from expert opinion (<a href="./references#CD007989-bbs2-0167" title="ThibautF , De LaBarraF , GordonH , CosynsP , BradfordJM , WFSBP Task Force on Sexual Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias. World Journal of Biological Psychiatry2010;11(4):604‐55. ">Thibaut 2010</a>). Although the studies reviewed show a mixed response as regards the side effects associated with the medication, all of these were of relatively short duration so that the response to their chronic usage may have more serious consequences. Berlin suggests that the risks of androgen deprivation treatment, in association with a proper protocol for prostate cancer patients, are broadly similar to other commonly prescribed psychotropics (<a href="./references#CD007989-bbs2-0077" title="BerlinFS . Risk/benefit ratio of androgen deprivation treatment for sex offenders. Journal of the American Academy of Psychiatry and the Law2009;37(1):59‐62. ">Berlin 2009</a>), and investigators must remain alert to minimising these risks where possible (<a href="./references#CD007989-bbs2-0062" title="AhmadiH , DaneshmandS . Androgen deprivation therapy: evidence‐based management of side effects. British Journal of Urology International2013;111(4):543‐8. ">Ahmadi 2013</a>). Investigators must also remain alert to the possibility of a treatment effect being undermined by exercise or by other medications used to undermine the effect of antilibidinals (<a href="./references#CD007989-bbs2-0084" title="CormieP , NewtonRU , TaaffeDR , SpryN , Joseph , D , AkhlilH , et al. Exercise maintains sexual activity in men undergoing androgen suppression for prostate cancer: a randomized controlled trial. Prostate Cancer and Prostatic Diseases2013;16(2):170‐5. ">Cormie 2013</a>; <a href="./references#CD007989-bbs2-0131" title="LeeS , KangS , JiD , BaeckS , LeeS , OhSM , et al. Quantitative LC‐MS/MS method in urine for the detection of drugs used to reverse the effects of chemical castration. Analytical and Bioanalytical Chemistry2013;405(10):3185‐94. ">Lee 2013</a>), as well as being mindful of the 'rebound effect' in testosterone levels and fantasising following cessation of some types of treatment (<a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>; <a href="./references#CD007989-bbs2-0036" title="KooKC , ShimGS , ParkHH , RhaKH , ChoiYD , ChungBH , et al. Treatment outcomes of chemical castration on Korean sex offenders. Journal of Forensic and Legal Medicine2013;20(6):563‐6. ">Koo 2013</a>; <a href="./references#CD007989-bbs2-0037" title="KooKC , LeeDH , KimKH , LeeSH , HongCH , HongSJ , et al. Unrecognized kinetics of serum testosterone: impact on short‐term androgen deprivation therapy for prostate cancer. Yonsei Medical Journal2014;55(3):570‐5. ">Koo 2014</a>). </p> <p>Third, trials hitherto may have lacked a specific rationale for their intervention. However, recent advances may have changed this thinking. The use of serotonergic antidepressants (SSRIs), for instance, to target the obsessional preoccupation of sexual offenders would require that they be prescribed at a high dose for a sufficient period. Similarly, the use of gonadotropin‐releasing hormone (GnRH) drugs (used in the treatment of prostate carcinoma) has been reported to be effective in case series of those who are at high risk of sexual offending (<a href="./references#CD007989-bbs2-0052" title="RöslerA , WitztumE . Treatment of men with paraphilia with a long‐acting analogue of gonadotropin‐releasing hormone. New England Journal of Medicine1998;338(7):416‐22. ">Rösler 1998</a>). </p> <p>Lastly, the difficulty in attracting a sufficient number of participants into trials is well recognised (<a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>), and has recently been reported as the reason for the termination of a trial in Norway (<a href="./references#CD007989-bbs2-0048" title="NøttestadJA . Cognitive and hormonal treatment of sex offenders. www.clinicaltrials.gov/show/NCT00379626 (accessed 7 June 2014). ">NCT00379626</a>). This may be due to a number of factors involving typical characteristics of sex offenders, including denial, cognitive distortion, and antisocial attitudes (<a href="./references#CD007989-bbs2-0115" title="HansonRK , Morton‐BourgonKE . The characteristics of persistent sexual offenders: a meta‐analysis of recidivism studies. Journal of Consulting and Clinical Psychology2005;73(6):1154‐63. ">Hanson 2005</a>), as well as the intrinsic consequences of the use of antilibidinal medication, such as stigma, and psychological effects such as perceived demasculinisation (<a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a>). Small numbers in trials is a common theme and inevitably affects the power and duration of studies, the homogeneity of participants, the scope for logistical regression, and ultimately, the quality of evidence available. </p> <p>Given that a significant proportion of those detained in prisons in the UK and elsewhere have been convicted of a sexual offence, there is no excuse that this is not a legitimate area in which to conduct a randomised controlled trial using medication. This ought to include a homogeneous population (i.e., rapists or paedophiles) with a clear rationale for its use together with an appropriate follow‐up period (minimally five years). Initially, these active treatments ought to be trialled against whatever treatment is currently being offered before proceeding to more complex 'head to head' trials, should the evidence warrant it. Attention should also be paid to comorbidities (generally mood disorders, anxiety disorders, psychoactive substance abuse disorders, attention deficit hyperactivity disorder (ADHD), and neuropsychological conditions), which appear to occur more frequently than expected in sexually impulsive men (<a href="./references#CD007989-bbs2-0081" title="BrikenP , KafkaMP . Pharmacological treatment for paraphilic patients and sexual offenders. Current Opinion in Psychiatry2007;20(6):609‐13. ">Briken 2007</a>). </p> <p>Although these recommendations appear to set the bar at a high level, the failure to do so in the past has meant that uncertainty continues with detrimental effects for both perpetrator and victim. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007989-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007989-sec-0029"></div> <section id="CD007989-sec-0030"> <h3 class="title" id="CD007989-sec-0030">Description of the condition</h3> <p>Sexual offending is a legal construct which overlaps, but is not necessarily congruent with, the clinical constructs of disorders of sexual preference as described in the <i>ICD‐10 Classification of Mental and Behavioural Disorders</i> (<a href="./references#CD007989-bbs2-0172" title="World Health Organization. The ICD‐10 Classification of Mental and Behavioural Disorders. Geneva: World Health Organization, 1992. ">WHO 1992</a>), or paraphilias as described in the <i>Diagnostic and Statistical Manual of Mental Disorders</i> (Fourth Edition‐Revised) (<a href="./references#CD007989-bbs2-0068" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV). Washington, DC: American Psychiatric Association, 1994. ">APA 1994</a>). Most, but not all, sexual offences are disorders of sexual preference and most, but not all, disorders of sexual preference are sexual offences. For instance, clinically defined sexual behaviours such as paedophilia, voyeurism, frotteurism, exhibitionism, zoophilia, and necrophilia also meet the rubric for sexual offences but, for instance, fetishism and transvestic fetishism do not, in many jurisdictions. Crimes such as rape and incest with consenting adult participants are not of themselves classified as disorders of sexual preference or paraphilias (<a href="./references#CD007989-bbs2-0108" title="GrubinD . Medical models and interventions in sexual deviance. In: LawsDR , O'DonohueW editor(s). Sexual Deviancy: Theory, Assessment and Treatment. 2nd Edition. New York: The Guildford Press, 2008. ">Grubin 2008</a>). </p> <p>The true prevalence of sexual offending is unknown. Sexual offending accounts for only 1% of crimes recorded in England and Wales (<a href="./references#CD007989-bbs2-0092" title="EastmanN , AdsheadG , FoxS , LathamR , WhyteS . Forensic Psychiatry (Oxford Specialist Handbooks in Psychiatry). Oxford: Oxford University Press (OSH Psychiatry), 2012. ">Eastman 2012</a>). In the US, 9.7% of prisoners have a history of sexual offending (<a href="./references#CD007989-bbs2-0107" title="GreenfeldLA . Sex offences and offenders: an analysis of data on rape and sexual assault. www.mincava.umn.edu/documents/sexoff/sexoff.html (accessed 1 August 2012). ">Greenfeld 1997</a>), with a figure of 13.3% reported in Australia (<a href="./references#CD007989-bbs2-0104" title="GelbK . Recividism of sex offenders research paper. http://goo.gl/uGmOrg (accessed 13 February 2014). ">Gelb 2007</a>). These figures are similar to the 10% reported by Taylor et al (<a href="./references#CD007989-bbs2-0166" title="TaylorPJ , LeeseM , WilliamsD , ButwellM , DalyR , LarkinE . Mental disorder and violence. A special (high security) hospital study. British Journal of Psychiatry1998;172(3):218‐26. ">Taylor 1998</a>) and Duggan et al (<a href="./references#CD007989-bbs2-0090" title="DugganCF , HollinCR , HubandN , ClarkeM , McCarthyL , DaviesS . A comparison of mentally disordered male offenders with and without a sexual offence: their characteristics and outcome. Sex Offender Treatment2013;8(1):1‐8. ">Duggan 2013</a>) for high security and medium security hospitals in the UK. They represent significant underestimates of the extent of the problem as many sexual offences are not reported or, if they are reported, the allegations are often subsequently withdrawn. The true proportion of offenders in custody may be only 0.7% of those responsible for offences (<a href="./references#CD007989-bbs2-0097" title="FarrowS [pers comm] . Permission to use a figure from K Gelb's 2007 'Recividism of Sex Offenders Research Paper' [personal communication]. Email to: J Dennis and colleagues 1 October 2012. ">Farrow 2012</a>) ‐ see <a href="#CD007989-fig-0001">Figure 1</a> (<a href="./references#CD007989-bbs2-0104" title="GelbK . Recividism of sex offenders research paper. http://goo.gl/uGmOrg (accessed 13 February 2014). ">Gelb 2007</a>). Surveys and reviews show a high incidence of victimisation (<a href="./references#CD007989-bbs2-0122" title="HoodR , ShuteS , FeilzerM , WilcoxA . Sex offenders emerging from long‐term imprisonment. A study of their long‐term reconviction rates and of parole board members' judgements of their risk. British Journal of Criminology2002;42(2):371‐94. ">Hood 2002</a>; <a href="./references#CD007989-bbs2-0093" title="EdwardsVJ , HoldenGW , FelittiVJ , AndaRF . The relationship between multiple forms of childhood maltreatment and adult mental health in community respondents: results from the adverse childhood experience study. American Journal of Psychiatry2003;160(8):1453‐9. ">Edwards 2003</a>; <a href="./references#CD007989-bbs2-0083" title="ChapmanDP , WhitfieldCL , FelittiVJ , DubeSR , EdwardsVJ , AndaRF . Adverse childhood experiences and the risk of depressive disorders in adulthood. Journal of Affective Disorders2004;82(2):217‐25. ">Chapman 2004</a>; <a href="./references#CD007989-bbs2-0076" title="BarthJ , BermetzL , HeimE , TrelleS , ToniaT . The current prevalence of child sexual abuse worldwide: a systematic review and meta‐analysis. International Journal of Public Health2013;58(3):469‐83. ">Barth 2013</a>; <a href="./references#CD007989-bbs2-0060" title="AbrahamsN , DevriesK , WattsC , PallittoC , PetzoldM , ShamuS , et al. Worldwide prevalence of non‐partner sexual violence: a systematic review. Lancet2014;383(9929):1648‐54. ">Abrahams 2014</a>), as well as high levels of psychiatric morbidity (<a href="./references#CD007989-bbs2-0139" title="McCauleyJ , KernDE , KolodnerK , DillL , SchroederAF , DeChantHK , et al. Clinical characteristics of women with a history of childhood abuse. JAMA1997; Vol. 277, issue 17:1362‐8. ">McCauley 1997</a>; <a href="./references#CD007989-bbs2-0121" title="HillJ , DavisR , ByattM , BurnsideE , RollinsonL , FearS . Childhood sexual abuse and affective symptoms in women: a general population study. Psychological Medicine2000;30(6):1283‐91. ">Hill 2000</a>; <a href="./references#CD007989-bbs2-0143" title="MolnarBE , BukaSL , KesslerRC . Child sexual abuse and subsequent psychopathology: results from the National Comorbidity Survey. American Journal of Public Health2001;91(5):753‐60. ">Molnar 2001</a>; <a href="./references#CD007989-bbs2-0165" title="SwanstonHY , PlunkettAM , O'TooleBI , ShrimptonS , ParkinsonPN , OatesRK . Nine years after child sexual abuse. Child Abuse &amp; Neglect2003; Vol. 27, issue 8:967‐84. ">Swanston 2003</a>; <a href="./references#CD007989-bbs2-0083" title="ChapmanDP , WhitfieldCL , FelittiVJ , DubeSR , EdwardsVJ , AndaRF . Adverse childhood experiences and the risk of depressive disorders in adulthood. Journal of Affective Disorders2004;82(2):217‐25. ">Chapman 2004</a>; <a href="./references#CD007989-bbs2-0142" title="MchichiAK , KadriN . Moroccan women with a history of child sexual abuse and its long‐term repercussions: a population‐based epidemiological study. Archives of Women's Mental Health2004; Vol. 7, issue 4:237‐42. ">Mchichi 2004</a>). </p> <div class="figure" id="CD007989-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="From Gelb 2007 (used with permission of the Sentencing Advisory Council, Melbourne, Victoria, Australia)" data-id="CD007989-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007989.pub2/media/CDSR/CD007989/image_n/nCD007989-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>From <a href="./references#CD007989-bbs2-0104" title="GelbK . Recividism of sex offenders research paper. http://goo.gl/uGmOrg (accessed 13 February 2014). ">Gelb 2007</a> (used with permission of the Sentencing Advisory Council, Melbourne, Victoria, Australia) </p> </div> </div> </div> <p>Legislative provisions reflect widespread societal concern. For instance, in the UK, provisions in the Sexual Offences Act 2003 include substantial increases in sentence length and state control, in terms of notification requirements and supervision, for up to 10 years after a sentence has been spent (<a href="./references#CD007989-bbs2-0106" title="GreatBritain . Chapter 42. Sexual Offences Act 2003 Elizabeth II. London: The Stationery Office, 2003. [ISBN 9 780 105442035] ">Great Britain 2003</a>). Again, in England and Wales, the Mental Health Act was amended in 2008 so that sexual deviancy was no longer excluded as a criterion for compulsory detention (<a href="./references#CD007989-bbs2-0089" title="Department of Health. Code of Practice: Mental Health Act 1983 (Published pursuant to section 118 of the Act). London: The Stationery Office, 2008. ">DOH 2008</a>). In Germany, penal reform in 1998 made the treatment of sexual offenders mandatory for such offenders receiving a prison sentence of more than two years (<a href="./references#CD007989-bbs2-0134" title="LöselF , SchmuckerM . The effectiveness of treatment for sexual offenders: a comprehensive meta‐analysis. Journal of Experimental Criminology2005;1(1):117‐46. ">Lösel 2005</a>). Similarly, the treatment of mentally disordered offenders in the US includes state‐specific sexual predator laws that allow for the preventative detention of those believed to be at high risk of sexually offending in the future. Finally, also in the US, there is Megan's Law, which allows information on registered sex offenders against children to be made available to the community; a similar law is now in force in the UK (<a href="./references#CD007989-bbs2-0065" title="About Megan'sLaw . Megan's Law. www.about‐megans‐law.com/(accessed August 2008). ">AML 2007</a>; <a href="./references#CD007989-bbs2-0132" title="LipscombeS . Sarah’s law: the child sex offender disclosure scheme. www.parliament.uk/briefing‐papers/SN01692(accessed April 2013). ">Lipscombe 2012</a>). While this concern is understandable, other commentators have argued that exaggerating the danger that sexual offenders pose is problematic as it may increase public fear, and stigmatise and hinder rehabilitation of offenders who have changed their lifestyles, while wasting valuable resources on unnecessary surveillance (<a href="./references#CD007989-bbs2-0161" title="SoothillK , FrancisB , SandersonB , AckerleyE . Sex offenders: specialists, generalists or both? A 32‐year criminological study. British Journal of Criminology2000;40(1):56‐67. ">Soothill 2000</a>).  </p> <p>Although the<i>recorded</i> pattern of sexual reoffending is relatively infrequent, with reported rates of 13.4% over four to five years' follow‐up (<a href="./references#CD007989-bbs2-0112" title="HansonRK , BussiereMT . Predicting relapse: a meta‐analysis of sexual offender recidivism studies. Journal of Consulting and Clinical Psychology1998;66(2):348‐62. ">Hanson 1998</a>), long‐term follow‐up studies demonstrate that recividism may persist over a long period, especially for paedophilia (<a href="./references#CD007989-bbs2-0150" title="PrentkyRA , LeeAFS , KnightRA , CerceD . Recidivism rates among child molesters and rapists: a methodological analysis. Law and Human Behavior1997;21(6):635‐59. ">Prentky 1997</a>). This has two significant consequences for the design of trials and their interpretation. First, its low frequency means that the difference between the two trial conditions has to be substantial in order for an effect to be demonstrated. Second, since reoffending can occur many years after release, follow‐up needs to be long‐term in order to capture data from all of those who reoffend. </p> <p>The literature also recognises that those convicted of a sexual offence are not homogeneous: the most common distinction is drawn between rapists and child molesters, as these are deemed to have different aetiologies, presenting characteristics, and likelihood of reoffending over different time periods (<a href="./references#CD007989-bbs2-0150" title="PrentkyRA , LeeAFS , KnightRA , CerceD . Recidivism rates among child molesters and rapists: a methodological analysis. Law and Human Behavior1997;21(6):635‐59. ">Prentky 1997</a>; <a href="./references#CD007989-bbs2-0099" title="FirestoneP , BradfordJM , GreenbergDM , SerranGA . The relationship of deviant sexual arousal and psychopathy in incest offenders, extrafamilial child molesters, and rapists. Journal of the American Academy of Psychiatry and Law2000;28(3):303‐8. ">Firestone 2000</a>). Another important confounder in the interpretation of trial data is the degree of psychopathy possessed by the sexual offender, as those with high levels are less likely to benefit from treatment and more likely to reoffend (<a href="./references#CD007989-bbs2-0158" title="SetoM , BarbareeH . Psychopathy, treatment behavior, and sex offender recidivism. Journal of Interpersonal Violence1999;14(12):1235‐48. ">Seto 1999</a>; <a href="./references#CD007989-bbs2-0120" title="HildebrandM , DeRuiterC , DeVogelC . Psychopathy and sexual deviancy in treated rapists: association with sexual and nonsexual recidivism. Sexual Abuse: A Journal of Research and Treatment2004;16(1):1‐24. ">Hildebrand 2004</a>). </p> </section> <section id="CD007989-sec-0031"> <h3 class="title" id="CD007989-sec-0031">Description of the intervention</h3> <p>A companion review of psychological interventions for those who have sexually offended or are at risk of offending has recently been updated (<a href="./references#CD007989-bbs2-0127" title="KenworthyT , AdamsCE , BilbyC , Brooks‐GordonB , FentonM . Psychological interventions for those who have sexually offended or are at risk of offending. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD004858] ">Kenworthy 2003</a>; <a href="./references#CD007989-bbs2-0088" title="DennisJ , HubandN , KhanO , FerriterM , JonesH , PowneyM , et al. Psychological interventions for adults who have sexually offended or are at risk of offending. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD007507.pub2] ">Dennis 2012</a>), and it is important to note the underlying difference between the psychological and antilibidinal approaches with which this review is concerned (see below). The objective of psychological interventions is, in general, to change the sexual behaviour of the offender while leaving libido intact, whilst encouraging a change from non‐consensual to consensual sexual activity, with partners of appropriate (legal) age. In contrast, many (although not all) antilibidinal interventions, such as the pharmacological interventions reviewed here, are administered to diminish or altogether eradicate sexual desire and capacity (<a href="./references#CD007989-bbs2-0059" title="AbelGG , CandiceCA . The paraphilias. In: GelderMG , Lopez‐Ibor JrJJ , AndreasenNC editor(s). New Oxford Textbook of Psychiatry. Vol. 1, Oxford: Oxford University Press, 2000. ">Abel 2000</a>), either temporarily (to provide a 'window' in which psychological treatments may be attempted) or permanently. </p> <p>Surgical antilibidinal interventions, such as orchiectomy or orchidectomy (male castration) or neurosurgery, require a separate review. </p> <section id="CD007989-sec-0032"> <h4 class="title">Medication</h4> <p>Antilibidinal medications broadly fall within two categories, namely those hormonal medications that have a testosterone‐suppressing effect, and non‐hormonal medications that affect libido through other mechanisms. </p> <section id="CD007989-sec-0033"> <h5 class="title">Hormonal drug therapy</h5> <p>The three main classes of testosterone‐suppressing drugs used today include progestogens, antiandrogens, and gonadotropin‐releasing hormone (GnRH) analogues. Prior to the 1960s, oestrogens were prescribed in North America to treat sexually aggressive men but this practice has been discontinued (<a href="./references#CD007989-bbs2-0108" title="GrubinD . Medical models and interventions in sexual deviance. In: LawsDR , O'DonohueW editor(s). Sexual Deviancy: Theory, Assessment and Treatment. 2nd Edition. New York: The Guildford Press, 2008. ">Grubin 2008</a>). </p> <p>The commonly used testosterone‐suppressing drugs include medroxyprogesterone acetate (MPA), cyproterone acetate (CPA), triptorelin, and goserelin. </p> </section> <section id="CD007989-sec-0034"> <h5 class="title">Non‐hormonal drug therapy</h5> <p>Non‐hormonal drugs that affect libido through means other than via testosterone suppression include antipsychotics and serotonergic antidepressants (SSRI) (<a href="./references#CD007989-bbs2-0071" title="BaldwinD , MayersA . Sexual side effects of antipsychotic and antidepressant drugs. Advances in Psychiatric Treatment2003;9:202‐10. ">Baldwin 2003</a>). Selective serotonin reuptake inhibitors (SSRIs) have been associated with reduced libido and delayed orgasm in 60% to 70% of people taking them (<a href="./references#CD007989-bbs2-0144" title="MontejoAL , LlorcaG , IzquierdoJA , Rico‐VillademorosF . Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Journal of Clinical Psychiatry2001;62 Suppl 3:10‐21. ">Montejo 2001</a>).  </p> <p>Exact information on rates of administering medication to sexual offenders in practice are limited, as are precise data on the acceptability of treatments. Some data suggest that psychological treatment is considered acceptable by two‐thirds of offenders, but pharmacological treatment only by one‐third (<a href="./references#CD007989-bbs2-0145" title="Nagayama‐HallGC . Sexual offender recidivism revisited: a meta‐analysis of recent treatment studies. Journal of Consulting and Clinical Psychology1995;63(5):802‐9. ">Nagayama‐Hall 1995</a>). Researchers in Germany, concerned at the absence of data for drug use in a clinical context, recently conducted a survey of German forensic‐psychiatric hospitals and outpatient clinics and found that of 611 sex offenders, <i>"almost all were treated psychotherapeutically and 37% were receiving an additional pharmacological treatment"</i> (<a href="./references#CD007989-bbs2-0168" title="TurnerD , Basdekis‐JozsaR , BrikenP . Prescription of testosterone‐lowering medications for sex offender treatment in German forensic‐psychiatric institutions. Journal of Sexual Medicine2013;10(2):570‐8. ">Turner 2013</a>, p 570). Of the latter, 15.7% were treated with testosterone‐lowering medications (10.6% with a GnRH agonist and 5.1% with CPA); 11.5% with SSRIs, and 9.8% with antipsychotic medications. </p> </section> </section> </section> <section id="CD007989-sec-0035"> <h3 class="title" id="CD007989-sec-0035">How the intervention might work</h3> <section id="CD007989-sec-0036"> <h4 class="title">1.1 Testosterone‐suppressing drugs</h4> <p>Testosterone production in men is controlled by the hypothalamus, anterior pituitary, and the gonads. Gonadotrophin‐releasing hormone (GnRH) is released from the hypothalamus in a pulsatile manner, which stimulates the secretion of the gonadotrophins (luteinising hormone (LH) and follicle‐stimulating hormone (FSH)), from the anterior pituitary. LH acts on Leydig cells in the testes resulting in the production and secretion of testosterone, which, in turn, has a negative feedback effect on the anterior pituitary and hypothalamus. </p> <p>Testosterone has been linked to sexual development and drive in men (<a href="./references#CD007989-bbs2-0108" title="GrubinD . Medical models and interventions in sexual deviance. In: LawsDR , O'DonohueW editor(s). Sexual Deviancy: Theory, Assessment and Treatment. 2nd Edition. New York: The Guildford Press, 2008. ">Grubin 2008</a>). Testosterone has both organisational and activational effects on the nervous system. The former is associated with the structural development of the brain and the latter with the effect of testosterone on the organised brain (<a href="./references#CD007989-bbs2-0160" title="SiskCL . New insights into the neurobiology of sexual maturation. Sexual and Relationship Therapy2006;21(1):5‐14. ">Sisk 2006</a>). The effect of testosterone on sexual interest and arousal appears to be one of maintaining a level of spontaneous functionality as opposed to being stimulus bound (<a href="./references#CD007989-bbs2-0074" title="BancroftJ . Human Sexuality and its Problems. Edinburgh: Churchill Livingstone, 1989. ">Bancroft 1989</a>). These effects are not immediate and take several weeks to occur after a change in plasma testosterone levels (<a href="./references#CD007989-bbs2-0075" title="BancroftJ . The endocrinology of sexual arousal. Journal of Endocrinology2005;186(3):411‐27. ">Bancroft 2005</a>). </p> <p>The direct relationship between testosterone and sexual behaviour, however, is confounded by the link between testosterone and aggressive behaviour (<a href="./references#CD007989-bbs2-0080" title="BookAS , StarzykKB , QuinseyVL . The relationship between testosterone and sexual aggression: a meta‐analysis. Aggression and Violent Behaviour2001;6(6):579‐99. ">Book 2001</a>). In addition, there is evidence that behaviour may itself result in changes in plasma testosterone levels and that testosterone levels may be more closely associated with dominance (<a href="./references#CD007989-bbs2-0138" title="MazurA , LambT . Testosterone and dominance in men. Behavioural and Brain Sciences1980;21(3):353‐63. ">Mazur 1980</a>). </p> <p>GnRH analogues appear to be more effective than CPA and MPA in producing long‐term castration levels of testosterone (<a href="./references#CD007989-bbs2-0141" title="McEvoyG (editor) . AHFS Drug Information. Bethesda, Maryland: American Society of Health System Pharmacists, 1999. ">McEvoy 1999</a>). However, few studies address the issue of reversibility after long‐term use of greater than two years, bar one small cohort study (<a href="./references#CD007989-bbs2-0052" title="RöslerA , WitztumE . Treatment of men with paraphilia with a long‐acting analogue of gonadotropin‐releasing hormone. New England Journal of Medicine1998;338(7):416‐22. ">Rösler 1998</a>). GnRH analogues and MPA have been shown to produce histological changes, such as reduced Leydig cell numbers, in the testes of animals (<a href="./references#CD007989-bbs2-0070" title="AvariKM , BhiwgadeDA . Effect of depot medroxyprogesterone acetate and testosterone anathate on the testis of albino rats: ultrastructural and biochemical studies. Indian Journal of Experimental Biology1992;30(12):1118‐27. ">Avari 1992</a>; <a href="./references#CD007989-bbs2-0151" title="RaoMV , RoyGK , PrasannalataSN . Effect of medroxyprogesterone acetate and testosterone enanthate on vas deferens of rats. Indian Journal of Experimental Biology1998;36(2):157‐61. ">Rao 1998</a>; <a href="./references#CD007989-bbs2-0141" title="McEvoyG (editor) . AHFS Drug Information. Bethesda, Maryland: American Society of Health System Pharmacists, 1999. ">McEvoy 1999</a>). </p> <p>All three agents are associated with potential adverse effects (<a href="./references#CD007989-bbs2-0152" title="ReillyDR , DelvaNJ , HudsonRW . Protocols for the use of cyproterone, medroxyprogesterone, and leuprolide in the treatment of paraphilia. Canadian Journal of Psychiatry2000;45(6):559‐63. ">Reilly 2000</a>), such as precipitation or aggravation of cardiac conditions (<a href="./references#CD007989-bbs2-0087" title="DeVoogtHJ , SmithPH , Pavone‐MacalusoM , DePauwM , SuciuS . Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. Journal of Urology1986;135(2):303‐7. ">De Voogt 1986</a>; <a href="./references#CD007989-bbs2-0149" title="PierceEJ . Angina pectoris and myocardial infarction with the use of leuprolide acetate. American Journal of Obstetrics and Gynecology1995;172(4 Pt 1):1323. ">Pierce 1995</a>), gynaecomastia, weight gain, hot flushes, or depression (<a href="./references#CD007989-bbs2-0108" title="GrubinD . Medical models and interventions in sexual deviance. In: LawsDR , O'DonohueW editor(s). Sexual Deviancy: Theory, Assessment and Treatment. 2nd Edition. New York: The Guildford Press, 2008. ">Grubin 2008</a>). CPA has been associated with fatal liver toxicity (<a href="./references#CD007989-bbs2-0147" title="ParysBT , HamidS , ThomsonRG . Severe hepatocellular dysfunction following cyproterone acetate therapy. British Journal Urology1991;67(3):312‐30. ">Parys 1991</a>; <a href="./references#CD007989-bbs2-0155" title="RoilaF , CrinoL , CarloniG , NataliniG . Cyproterone acetate: hepatotoxicity and prostate cancer treatment. Annals of Oncology1993;4:701. ">Roila 1993</a>). An established consequence of low testosterone is osteoporosis (<a href="./references#CD007989-bbs2-0164" title="StĕpánJJ , LachmanM , ZvĕrinaJ , PacovskýV , BaylinkDJ . Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodelling. Journal of Clinical Endocrinology and Metabolism1989;69(3):523‐7. ">Stĕpán 1989</a>; <a href="./references#CD007989-bbs2-0157" title="SchotLPC , SchuursAHWM . Pathophysiology of bone loss in castrated animals. Journal of Steroid Biochemistry and Molecular Biology1990;37(3):461‐5. ">Schot 1990</a>), a potentially serious and difficult to manage side effect of testosterone suppression, which is more likely to occur with long‐term use of GnRH agonists. </p> </section> <section id="CD007989-sec-0037"> <h4 class="title">1.2 Drugs that decrease libido via mechanisms unrelated to testosterone suppression</h4> <p>Although the exact mechanisms are unclear, animal studies suggest that mesolimbic dopamine has an activating effect on sexual arousal and that serotonin has the opposite effect (<a href="./references#CD007989-bbs2-0124" title="HullEM , MuschampJW , SatoS . Dopamine and serotonin: influences on male sexual behaviour. Physiology and Behaviour2004;83(2):291‐307. ">Hull 2004</a>). In addition, dopamine antagonism may result in prolactin elevation, which may have an effect on libido (<a href="./references#CD007989-bbs2-0075" title="BancroftJ . The endocrinology of sexual arousal. Journal of Endocrinology2005;186(3):411‐27. ">Bancroft 2005</a>); such drugs may also positively impact on mental disorders prevalent in this population (e.g., depression, substance misuse, and personality disorder) (<a href="./references#CD007989-bbs2-0098" title="FazalS , GrannM . The population impact of severe mental illness on violent crime. American Journal of Psychiatry2006;163:1397‐403. ">Fazal 2006</a>). </p> <p>Both classes of medication in this category, although widely used, have potentially troublesome side effects. The adverse effects of antipsychotics include tardive dyskinesia (<a href="./references#CD007989-bbs2-0126" title="KaneJM . Tardive dyskinesia circa 2006. American Journal of Psychiatry2006;163(8):1316‐8. ">Kane 2006</a>), weight gain (<a href="./references#CD007989-bbs2-0064" title="AllisonDB , MentoreJL , HeoM , ChandlerLP , CappelleriJC , InfanteCM , et al. Antipsychotic‐induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry1997;156(11):1686‐96. ">Allison 1997</a>), and impaired glucose tolerance (<a href="./references#CD007989-bbs2-0110" title="HaddadPM . Antipsychotics and diabetes: review of non‐prospective data. British Journal of Psychiatry2004;184(47):S80‐6. ">Haddad 2004</a>). </p> <p>Selective serotonin reuptake inhibitors (SSRIs) are generally considered to have a more benign side effect profile than other antilibidinal interventions. However, SSRIs are associated with restlessness, agitation, and suicidality, particularly in the under 30 age group (<a href="./references#CD007989-bbs2-0085" title="Committee on Safety of Medicines (CSM). Safety of selective serotonin reuptake inhibitor antidepressants. http://goo.gl/okEvdJ(accessed May 2009). ">CSM Working Group 2004</a>), and they are also associated with an increased risk of bleeding (<a href="./references#CD007989-bbs2-0148" title="PatonC , FerrierIN . SSRIs and gastrointestinal bleeding. BMJ2005;331:529‐30. ">Paton 2005</a>).   </p> </section> </section> <section id="CD007989-sec-0038"> <h3 class="title" id="CD007989-sec-0038">Why it is important to do this review</h3> <p>Both the prevalence of sexual offending and the association between victimisation and subsequent mental health problems mean that these offences make a significant contribution to mental health morbidity and societal concern more generally. Therefore, there is strong social and political pressure to address this problem, not just in terms of helping the victims but in preventing sexual recidivism (<a href="./references#CD007989-bbs2-0113" title="HansonRK , HarrisAJR . Where should we intervene? Dynamic predictors of sexual offense recidivism. Criminal Justice and Behavior2000;27(1):6‐35. ">Hanson 2000</a>). </p> <p>Furby et al, in one of the first major reviews of sex offender recividism, concluded that there was little evidence for any intervention for sex offenders (<a href="./references#CD007989-bbs2-0101" title="FurbyL , WeinrottMR , BlackshawL . Sex offender recidivism: a review. Psychological Bulletin1989;105(1):3‐30. ">Furby 1989</a>). This report was criticised by Marshall and Pithers (<a href="./references#CD007989-bbs2-0136" title="MarshallWL , PithersWD . A reconsideration of treatment outcome with sex offenders. Criminal Justice and Behavior1994;21(1):10‐27. ">Marshall 1994</a>), as it contained several flaws, including potential biases against treatment effects, duplication of data, and reliance on outdated programmes. Nagayama‐Hall and colleagues subsequently published a meta‐analysis of 12 of the most recent treatment studies of sexual offenders and found a modest treatment effect for both cognitive behavioural and hormonal treatment, which were both significantly more effective than behavioural therapy but not significantly different from one another (<a href="./references#CD007989-bbs2-0145" title="Nagayama‐HallGC . Sexual offender recidivism revisited: a meta‐analysis of recent treatment studies. Journal of Consulting and Clinical Psychology1995;63(5):802‐9. ">Nagayama‐Hall 1995</a>).   </p> <p>An early Cochrane review looked at all types of interventions for sexual offending (<a href="./references#CD007989-bbs2-0171" title="WhiteP , BradleyC , FerriterM , HatzipetrouL . Managements for people with disorders of sexual preference and for convicted sexual offenders. Cochrane Database of Systematic Reviews1998, Issue 4. [DOI: 10.1002/14651858.CD000251] ">White 1998</a>); it was partially updated in 2003 in a review that considered only psychological interventions (<a href="./references#CD007989-bbs2-0127" title="KenworthyT , AdamsCE , BilbyC , Brooks‐GordonB , FentonM . Psychological interventions for those who have sexually offended or are at risk of offending. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD004858] ">Kenworthy 2003</a>, later updated as <a href="./references#CD007989-bbs2-0088" title="DennisJ , HubandN , KhanO , FerriterM , JonesH , PowneyM , et al. Psychological interventions for adults who have sexually offended or are at risk of offending. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD007507.pub2] ">Dennis 2012</a>). The older review identified only one small trial (n = 21) that compared antiandrogen medication (MPA) plus a psychological intervention versus the same psychological intervention and identified no significant difference between the two groups (<a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>). The review authors concluded that there were too few data to come to any conclusion about the effectiveness of MPA. </p> <p><a href="./references#CD007989-bbs2-0061" title="AdiY , AshcroftD , BrowneK , BeechA , Fry‐SmithA , HydeC . Clinical effectiveness and cost‐consequences of selective serotonin reuptake inhibitors in the treatment of sex offenders. Health Technology Assessment2002;6(28):1‐66. ">Adi 2002</a> reviewed the clinical effectiveness and cost‐consequences of SSRIs in the treatment of sex offenders but identified no RCTs and only nine case series studies with a total of 225 participants. The authors concluded that there were insufficient data of high enough quality to come to any conclusion. </p> <p>Subsequently, a systematic review by Lösel and Schmucker was produced which, like that by White et al, considered all treatment options for sex offenders but included studies of a larger range of designs (<a href="./references#CD007989-bbs2-0134" title="LöselF , SchmuckerM . The effectiveness of treatment for sexual offenders: a comprehensive meta‐analysis. Journal of Experimental Criminology2005;1(1):117‐46. ">Lösel 2005</a>). They reported a treatment effect size of 3.08 (95% confidence interval (CI) 1.40 to 6.79, P value &lt; 0.01) for antilibidinal medication based on six identified studies. However, the review does not report sample sizes or study designs for pharmacological interventions and the methodologies of the included studies were unclear. Briken and Kafka conducted a literature review of the area, which concluded that medication interventions "show definite promise" (p 609), but deplored the absence of randomised controlled trials and recommended pharmacological treatment be combined with other treatments, including cognitive behavioural therapy and community supervision (<a href="./references#CD007989-bbs2-0081" title="BrikenP , KafkaMP . Pharmacological treatment for paraphilic patients and sexual offenders. Current Opinion in Psychiatry2007;20(6):609‐13. ">Briken 2007</a>). </p> <p>There is, therefore, an urgent need for an up‐to‐date systematic review.</p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007989-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007989-sec-0039"></div> <p>To evaluate the effects of pharmacological interventions on target sexual behaviour for people who have been convicted or are at risk of sexual offending. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007989-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007989-sec-0040"></div> <section id="CD007989-sec-0041"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007989-sec-0042"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials, with or without blinding. We excluded quasi‐randomised trials such as those where allocation was undertaken on surname. </p> </section> <section id="CD007989-sec-0043"> <h4 class="title">Types of participants</h4> <p>Adults aged 18 years old and over, treated in institutional (prison or psychiatric facility) or community settings for sexual behaviours that have resulted in conviction or caution for sexual offences, offences with a sexual element, or violent behaviours with a sexual element (for example, sexual offences where murder is the index offence), or seeking treatment on a voluntary basis for behaviours that would be classified as illegal.   </p> <p>Defining what constitutes a sexual offence in the context of the international literature can be problematic as definitions of criminally sexual behaviour differ between jurisdiction, cultures, and over time. We decided to include trials of interventions where the participants had committed a sexual offence that would be accepted by most jurisdictions as crimes, viz. penetrative or non‐penetrative sexual acts carried out by adults on non‐consenting adult victims, and penetrative or non‐penetrative sexual acts carried out by adults on consenting or non‐consenting children or adults unable to give informed consent due to their physical or mental disability, or both. </p> <p><b>Excluded:</b> Studies of interventions for sex offenders where there was no clear international consensus as to whether the sexual behaviour was a crime or not (although it is possible that in two studies a minority of participants may no longer meet the criteria for being 'at risk' of a crime of a sexual nature (<a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>; <a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>)). General examples of exclusions include consenting same‐sex acts between adults, consenting sadomasochistic acts, and transvestitism. We also excluded interventions for sex offenders with learning disabilities as this is the subject of a separate Cochrane review (<a href="./references#CD007989-bbs2-0069" title="AshmanL , DugganL . Interventions for learning disabled sex offenders. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD003682.pub2] ">Ashman 2008</a>). </p> <p>In addition, we excluded studies concerning abnormal sexual behaviour/sexual disinhibition arising from dementia, as this is covered within the scope of the Cochrane Dementia and Cognitive Improvement Group. </p> </section> <section id="CD007989-sec-0044"> <h4 class="title">Types of interventions</h4> <p>Pharmacological interventions versus placebo or standard care (which might include psychological interventions or no treatment). Where psychological therapy was also a part of treatment, we only analysed comparable therapies within the same comparison. </p> </section> <section id="CD007989-sec-0045"> <h4 class="title">Types of outcome measures</h4> <section id="CD007989-sec-0046"> <h5 class="title">Primary outcomes</h5> <p><b>Sexual recidivism</b> as measured by reconviction, self report, or caution (a legal construct valid in the UK and Hong Kong in which an official warning is given by police to someone who has committed a minor offence but has not been charged, to the effect that further action will be taken if they commit another such offence) or by self report. </p> </section> <section id="CD007989-sec-0047"> <h5 class="title">Secondary outcomes</h5> <p><b>* Physiological capacity for sexual arousal</b> as measured by phallometric measures (for example, penile plethysmography or PPG); number of reported spontaneous erections; achieved orgasms; circulating levels of hormones, including plasma testosterone). </p> <p><b>* Sexually anomalous urges or sexual obsessions</b> ('sexually anomalous' behaviours was a term coined by the late Dr Neil McConaghy to cover "the broad range of sexual paraphilic behaviours including those that attracted criminal penalties...". The term was used to avoid pejorative connotations associated with terms such as 'deviant', 'aberrant' etc.) (<a href="./references#CD007989-bbs2-0078" title="BlaszczynskiA [pers comm] . Clarification of methods used in McConaghy 1983 and 1985 and confirmation that no data (means, standard deviations) remains on file. Reported that he knew of no other RCTs in the area [personal communication]. Email to: J Dennis 30‐31 August 2011. ">Blaszczynski 2011</a>). This measure aims to capture thoughts and behaviours that participants experience as negative, but which do not always result in a formal charge, or urges likely to lead to recidivism. Such urges may be assessed (for example) by diaries or scales of intrusive deviant fantasies. </p> <p><b>* Anxiety</b> as measured (for example) by the State‐Trait Anxiety Inventory (STAI) (<a href="./references#CD007989-bbs2-0162" title="SpielbergerCD . Manual for the State‐Trait Anxiety Inventory (STAI). Palo Alto, CA: Consulting Psychologists Press, 1983. ">Spielberger 1983</a>). </p> <p><b>* Anger or aggression</b> as measured (for example) by the State‐Trait Anger Expression Inventory‐2 (STAXI‐II) (<a href="./references#CD007989-bbs2-0163" title="SpielbergerCD . STAXI‐2: State‐Trait Anger Expression Inventory‐2. Odessa, FL: Psychological Assessment Resources, Inc, 1999. ">Spielberger 1999</a>). </p> <p><b>Dropping out of treatment.</b> </p> <p><b>Adverse events, including suicide or suicide attempts, and sudden or unexpected death, from any cause.</b> </p> <p>We divided outcomes into immediate (post‐treatment to within six months), short‐term (six months to 24 months), medium‐term (24 months to five years), and long‐term (beyond five years) during the period at risk, for example, post release from prison or discharge from hospital facility. If the participants were receiving treatment in the community then we considered the period at risk as including the period during treatment and also at maximum follow‐up. </p> <p><b>*</b> Starred outcomes were added post‐protocol and are justified as follows: </p> <p>As investigators comment, in some studies, "the population studied is one compulsorily detained" and "although this provides certain advantages, it does mean that there will be no opportunities for the deviant behavior which brought the subjects into hospital" and "therefore, other variables relevant to sexual behavior need to be measured" (p 263) (<a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>). </p> <p>The rationale for adding the outcomes asterisked above was based on research concerning dynamic risk factors in sex offending. They have also been added to the companion review to this one, which assesses psychological outcomes for sex offenders (<a href="./references#CD007989-bbs2-0088" title="DennisJ , HubandN , KhanO , FerriterM , JonesH , PowneyM , et al. Psychological interventions for adults who have sexually offended or are at risk of offending. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD007507.pub2] ">Dennis 2012</a>). These changes may be important for sex offenders yet to be released who have little opportunity to reoffend and so should also be reported on (especially those like anxiety and anger, which may particularly be affected by pharmacological action that suppresses testosterone). </p> <p>In contrast to the review on psychological interventions, we did not include the outcome of 'cognitive distortions' (a dynamic risk factor according to <a href="./references#CD007989-bbs2-0113" title="HansonRK , HarrisAJR . Where should we intervene? Dynamic predictors of sexual offense recidivism. Criminal Justice and Behavior2000;27(1):6‐35. ">Hanson 2000</a>), as these are not generally targets of pharmacological therapy except when the latter is used to create a 'window' in which psychological therapies may be used within the context of combined modality therapy. </p> <p>We did add the outcome of "physiological capacity for sexual arousal", as this is an important target of pharmacological rather than psychological treatments (particularly for those with diagnoses of paraphilias). </p> <p>Appreciating that different investigators were interested in different aspects of physiological arousal in accordance with the hypothesised mechanism of the drug under investigation, we were careful to record intended action as well as results. As one set of investigators note, "Castration itself is not necessarily followed by loss of libido" (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>, p 262), so it may be important to assess physiological arousal (for example, via PPG) in concert with psychological arousal (for example, urges or obsessions). </p> </section> </section> </section> <section id="CD007989-sec-0048"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007989-sec-0049"> <h4 class="title">Electronic searches</h4> <p>We ran the first set of searches in July 2008. We updated them in 2010, again in 2013, and most recently in July 2014. We searched the following databases: </p> <p> <ul id="CD007989-list-0001"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL 2014, Issue 7), 8 July 2014.</p> </li> <li> <p>Ovid MEDLINE, 1950 to 8 July 2014.</p> </li> <li> <p>EMBASE (Ovid), 1980 to 8 July 2014.</p> </li> <li> <p>AMED ‐ Allied and Complementary Medicine, 1985 to 8 July 2014.</p> </li> <li> <p>ASSIA ‐ Applied Social Sciences Index and Abstracts (CSA), 1987 to 8 July 2014.</p> </li> <li> <p>Biosis Previews, 1985 to 9 July 2014.</p> </li> <li> <p>CINAHL (EBSCO host), 1982 to 9 July 2014.</p> </li> <li> <p>Copac Academic and National Library Catalogue, last searched January 2008.</p> </li> <li> <p>IBSS ‐ International Bibliography of the Social Sciences, 1951 to 8 July 2014.</p> </li> <li> <p>ISI Proceedings, 1990 to 9 July 2014.</p> </li> <li> <p>ISI‐SCI ‐ Science Citation Index Expanded, 1970 to 9 July 2014.</p> </li> <li> <p>ISI‐SSCI ‐ Social Sciences Citation Index, 1970 to 9 July 2014.</p> </li> <li> <p>National Criminal Justice Reference Service Abstracts Database, last searched 10 July 2014. </p> </li> <li> <p>OpenSIGLE, last searched July 2008.</p> </li> <li> <p>ProQuest Dissertations and Theses, last searched 8 July 2014.</p> </li> <li> <p>PsycINFO (Ovid), 1806 to 9 July 2014.</p> </li> <li> <p>Social Care Online, last searched 9 July 2014.</p> </li> <li> <p>Sociological Abstracts, 1952 to 9 July 2014.</p> </li> <li> <p>ZETOC, last searched September 2010.</p> </li> </ul> </p> <p>The OpenSIGLE website was being redesigned at the time of searching in 2010 and the export function was not available; test searches of OpenGrey in 2013 were unproductive and we decided not to run further searches in this database. We searched ZETOC up until 2010, but not for later updates because of the large volume of irrelevant records. Any relevant records were also found in other databases. </p> <p>In addition, we added searches of two clinical trials registers for this update:</p> <p> <ul id="CD007989-list-0002"> <li> <p>International Clinical Trials Registry Platform (ICTRP; <a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>) (8 July 2014); </p> </li> <li> <p>Clinicaltrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">http://clinicaltrials.gov/</a>) (8 July 2014). </p> </li> </ul> </p> <p>We used randomised controlled trial filters as appropriate. We applied no restrictions based on language, date, or publication status. See <a href="./appendices#CD007989-sec-0173">Appendix 1</a> for the full list of databases and search terms used. </p> <p>We constructed the electronic searches taking into account the changing terminology and perception of sex offences. We recognise that several of these terms would now be regarded as unacceptable or misleading, or both, as terms signifying sexual offending. </p> </section> <section id="CD007989-sec-0050"> <h4 class="title">Searching other resources</h4> <section id="CD007989-sec-0051"> <h5 class="title">Handsearching</h5> <p>We searched reference lists of included studies for additional relevant trials along with the reference lists of reviews. </p> </section> <section id="CD007989-sec-0052"> <h5 class="title">Requests for additional data</h5> <p>We attempted to contact investigators from each included study and we contacted known experts in the field for information regarding unpublished data or ongoing studies, or both. These included Paul Federoff (Canada), Don Grubin (UK), Markus Kruesi (USA), Stephen Hucker (Canada), and Martin Kafka (USA). </p> </section> </section> </section> <section id="CD007989-sec-0053"> <h3 class="title" id="CD007989-sec-0053">Data collection and analysis</h3> <p>Except where indicated in <a href="#CD007989-sec-0186">Differences between protocol and review</a>, we followed the methods outlined in the protocol for this review (<a href="./references#CD007989-bbs2-0173" title="KhanO , FerriterM , HubandN , SmailagicN . Pharmacological interventions for those who have sexually offended or are at risk of offending. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007989] ">Khan 2009</a>). </p> <section id="CD007989-sec-0054"> <h4 class="title">Selection of studies</h4> <p>A minimum of two review authors working in pairs (NH, MF, OK, JD, and MP) independently read and assessed the titles and abstracts of studies identified through searches of electronic databases. Two review authors (NH, MF or JD) then independently assessed full copies of those papers that appeared to meet the inclusion criteria. We resolved uncertainties concerning the appropriateness of studies for inclusion in the review through consultation with a third review author (OK). Review authors were not blinded to the name(s) of the study author(s), their institution(s), or publication sources at any stage of the review. </p> </section> <section id="CD007989-sec-0055"> <h4 class="title">Data extraction and management</h4> <p>Two authors (MF, NH and/or JD) extracted data independently using a piloted data extraction form. We extracted information on study design and implementation, setting, sample characteristics, intervention characteristics, and outcomes from all included studies. NH, JD, and/or OK entered data into Review Manager 5 (RevMan) software (<a href="./references#CD007989-bbs2-0153" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). Where data were not available in the published trial reports, we contacted the authors and asked them to supply the missing information. </p> </section> <section id="CD007989-sec-0056"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For each included study, two review authors (MF, NH, and/or JD) independently completed The Cochrane Collaboration's tool for assessing risk of bias (<a href="./references#CD007989-bbs2-0118" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). This required authors to assess the degree to which: </p> <p> <ul id="CD007989-list-0003"> <li> <p>the allocation sequence was adequately generated ('sequence generation');</p> </li> <li> <p>the allocation was adequately concealed ('allocation concealment');</p> </li> <li> <p>knowledge of the allocated interventions was adequately prevented during the study ('blinding'); </p> </li> <li> <p>incomplete outcome data were adequately addressed;</p> </li> <li> <p>reports of the study were free of suggestion of selective outcome reporting.</p> </li> </ul> </p> <p>We made assessments for each domain as 'low', 'unclear', or 'high' risk of bias.</p> <section id="CD007989-sec-0057"> <h5 class="title">Sequence generation</h5> <p>We determined whether studies used computer‐generated random numbers, table of random numbers, drawing lots or envelopes, coin tossing, shuffling cards, or throwing dice. </p> <p> <ul id="CD007989-list-0004"> <li> <p>Low risk: the study authors explicitly stated that they used one of the above methods.</p> </li> <li> <p>High risk: the authors did not use any of the above methods.</p> </li> <li> <p>Unclear: there is no information on the randomisation method or it is not clearly presented. </p> </li> </ul> </p> </section> <section id="CD007989-sec-0058"> <h5 class="title">Allocation concealment</h5> <p>We evaluated whether investigators and participants could foresee assignments before screening was complete and consent was given. </p> <p> <ul id="CD007989-list-0005"> <li> <p>Low risk: researchers and participants were unaware of future allocation to treatment conditions. </p> </li> <li> <p>High risk: allocation was either not used or was not concealed from researchers before eligibility was determined or from participants before consent was given. </p> </li> <li> <p>Unclear: information regarding allocation concealment is not known or not clearly presented. </p> </li> </ul> </p> </section> <section id="CD007989-sec-0059"> <h5 class="title">Blinding of participants and personnel</h5> <p> <ul id="CD007989-list-0006"> <li> <p>Low risk: participants and personnel were blinded to the treatment conditions.</p> </li> <li> <p>High risk: there is doubt about the placebo control via differences in appearance, mode of administration etc. </p> </li> <li> <p>Unclear: information on the blinding of participants is unclear or unavailable from study authors. </p> </li> </ul> </p> </section> <section id="CD007989-sec-0060"> <h5 class="title">Blinding of outcome assessment</h5> <p> <ul id="CD007989-list-0007"> <li> <p>Low risk: assessors were blinded to the treatment conditions.</p> </li> <li> <p>High risk: assessors were not blinded to the treatment conditions.</p> </li> <li> <p>Unclear: information on the blinding of assessors is unclear or unavailable from study authors. </p> </li> </ul> </p> </section> <section id="CD007989-sec-0061"> <h5 class="title">Incomplete outcome data</h5> <p> <ul id="CD007989-list-0008"> <li> <p>Low risk: no participants dropped out or were excluded from treatment; there are some missing data but the reasons for missing data are unlikely to be related to the true outcome; or missing data are balanced in proportion across intervention groups, with similar reasons for missing data across groups. </p> </li> <li> <p>High risk: there is differential attrition across groups; reasons for dropping out of treatment are different across groups; there was inappropriate application of simple imputation. </p> </li> <li> <p>Unclear: the attrition rate is unclear or the authors state that intention‐to‐treat (ITT) analysis was used but provide no details. </p> </li> </ul> </p> </section> <section id="CD007989-sec-0062"> <h5 class="title">Selective reporting bias</h5> <p>To assess outcome reporting bias, we attempted to collect all study reports (and protocols, where possible) and tracked the collection and reporting of outcome measures across all available reports within each included study. </p> <p> <ul id="CD007989-list-0009"> <li> <p>Low risk: a protocol is available and all outcome measures and follow‐ups are reported; or, a study protocol is not available but it seems clear that the published report included all expected outcomes, including those that were pre‐specified. </p> </li> <li> <p>High risk: data from some outcome measures are reported partially (e.g., means but no standard deviations (SD)) or without numerical data and only as 'ns' (non‐significant) or not at all. </p> </li> <li> <p>Unclear risk: it is not clear whether all data collected by study authors were reported.</p> </li> </ul> </p> </section> <section id="CD007989-sec-0063"> <h5 class="title">Other sources of bias</h5> <p>To assess other sources of bias not detailed above, we scanned all reports of included studies to attempt to ascertain whether other factors (either within or outside the control of investigators) might have introduced bias. These might have included (for example) the nature of recruitment procedures, the source of funding for the trial, changes to definitions of offending over time, etc. We supplied ratings as follows for each study: </p> <p> <ul id="CD007989-list-0010"> <li> <p>Low risk: no issues likely to bias the results of the trial (apart from those elsewhere dealt with within the 'Risk of bias' tool) were identified; </p> </li> <li> <p>High risk: issues likely to bias the results of the trial identified and judged serious; and </p> </li> <li> <p>Unclear risk: it is not clear whether relevant issues identified as being likely to bias the trial did in fact do so (or if so, in what direction the bias was likely to be directed). </p> </li> </ul> </p> </section> </section> <section id="CD007989-sec-0064"> <h4 class="title">Measures of treatment effect</h4> <p>All primary outcomes and (originally) all secondary outcomes were dichotomous and we planned to use the risk ratio (RR) with a 95% confidence interval (CI) to summarise results within each study. Some secondary outcomes introduced post‐protocol have been reported as continuous outcomes. Whilst no meta‐analysis has been possible in this review, we plan at update to report these as mean differences with a 95% CI. Where different scales measure the same outcome, we will calculate standardised mean differences (SMDs). </p> <p>We planned comparisons for specific follow‐up periods:</p> <p> <ul id="CD007989-list-0011"> <li> <p>within the first six months;</p> </li> <li> <p>between six and 24 months;</p> </li> <li> <p>between 24 months and five years;</p> </li> <li> <p>beyond five years.</p> </li> </ul> </p> </section> <section id="CD007989-sec-0065"> <h4 class="title">Unit of analysis issues</h4> <section id="CD007989-sec-0066"> <h5 class="title">Cross‐over trials</h5> <p>The method planned at protocol stage was to use data from any cross‐over trials as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007989-bbs2-0117" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), using approximated paired analysis by imputing missing standard deviations and with due attention to other recommendations in section 16.4 (<a href="./references#CD007989-bbs2-0119" title="HigginsJPT , DeeksJJ , AltmanDG . Chapter 16. Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). </p> </section> <section id="CD007989-sec-0067"> <h5 class="title">Multiple treatment arms</h5> <p>In the protocol originally produced for this review we neglected to state our plans for handling studies in which more than one eligible treatment was compared with control. Whilst this does not affect the current results, for future updates we plan to treat such studies as follows: </p> <p>a) in the event that two or more intervention arms test treatments that would (if employed against similar controls in separate trials) be amenable to combining in a meta‐analysis within our review, then we will pool data from both eligible arms against control. An example of such a study might be one in which different dosages of a drug were compared against placebo; </p> <p>b) if, in contrast, trials compare two eligible interventions with an eligible control but the former are not sufficiently similar that they merit pooling (for example, should a SSRI be trialled alongside a GnRH agonist against a shared control), we will treat the study as two studies and divide the data from the control group in half (so as to avoid double counting of control group participant data). </p> <p>We will transparently document all decisions made in regard to such studies.</p> </section> </section> <section id="CD007989-sec-0068"> <h4 class="title">Dealing with missing data</h4> <p>We assessed missing data and the number of participants that dropped out of treatment for each included study and reported the number of participants who were included in the final analysis as a proportion of all randomised participants in each study. We provided reasons, where known, for missing data in the narrative summary, as well as details of the investigators' use of intention‐to‐treat (ITT) analysis (where applicable). </p> </section> <section id="CD007989-sec-0069"> <h4 class="title">Assessment of heterogeneity</h4> <p>We did not undertake a meta‐analysis because of the heterogeneity of interventions and outcome measures used, and because of concerns regarding carry‐over effects from some cross‐over studies, especially <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>. </p> <p>Plans for assessing statistical consistency of results of any meta‐analysis in future updates can be found in <a href="./appendices#CD007989-sec-0174">Appendix 2</a>; clinical heterogeneity within the present review is described in detail in the following sections: <a href="#CD007989-sec-0075">Description of studies</a>, <a href="#CD007989-sec-0099">Effects of interventions</a>, and in the <a href="#CD007989-sec-0158">Discussion</a>. </p> </section> <section id="CD007989-sec-0070"> <h4 class="title">Assessment of reporting biases</h4> <p>We identified insufficient comparable trials for funnel plots to be feasible for this version of the review. See <a href="./appendices#CD007989-sec-0174">Appendix 2</a>. </p> </section> <section id="CD007989-sec-0071"> <h4 class="title">Data synthesis</h4> <p>We originally planned to synthesise data using both a fixed‐effect and a random‐effects model. In the event, no meta‐analysis was possible and all results are reported narratively below. </p> <p>See <a href="./appendices#CD007989-sec-0174">Appendix 2</a> for plans for data synthesis for future versions of the review. </p> </section> <section id="CD007989-sec-0072"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We identified insufficient comparable trials for subgroup analysis to be possible for this version of the review. See <a href="./appendices#CD007989-sec-0174">Appendix 2</a>. </p> </section> <section id="CD007989-sec-0073"> <h4 class="title">Sensitivity analysis</h4> <p>We identified insufficient comparable trials for sensitivity analysis to be possible for this version of the review. See <a href="./appendices#CD007989-sec-0174">Appendix 2</a>. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007989-sec-0074" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007989-sec-0074"></div> <section id="CD007989-sec-0075"> <h3 class="title">Description of studies</h3> <p>See also <a href="./references#CD007989-sec-0188" title="">Characteristics of included studies</a>. </p> <section id="CD007989-sec-0076"> <h4 class="title">Results of the search</h4> <p>We performed electronic searches over four consecutive time periods (2008, 2010, 2013, and July 2014). Searches were not restricted to pharmacological interventions, but included terms relevant to the companion review on psychological interventions for the same population (<a href="./references#CD007989-bbs2-0088" title="DennisJ , HubandN , KhanO , FerriterM , JonesH , PowneyM , et al. Psychological interventions for adults who have sexually offended or are at risk of offending. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD007507.pub2] ">Dennis 2012</a>). Due to the degree of overlap between these searches, and the fact that fewer studies related to pharmacological treatment than to psychological treatment, we judge it uninformative to produce a flowchart of selection, but report data narratively. </p> <p>Searches to 2008 yielded 26,197 records (of which we examined 343 in full text).</p> <p>Searches from September 2008 to October 2010 produced 10,507 records, of which we examined 53 in full text. </p> <p>Searches run in June 2013, covering the period of 2010 to June 2013, resulted in 6228 records, of which we assessed nine in full text. From these 405 records, we extracted data on eight studies; we excluded one study following clarification from the author regarding lack of a placebo control (<a href="./references#CD007989-bbs2-0041" title="Kruesi MJP [perscomm] . Clarification sought on methods [personal communication]. Email and telephone conversation with: J Dennis 27‐28 March 2012. KruesiMJP , FineS , ValladaresL , PhillipsRA , RapoportJL . Paraphilias: a double‐blind crossover comparison of clomipramine versus desipramine. Archives of Sexual Behavior1992;21(6):587‐93. ">Kruesi 1992</a>). </p> <p>Searches run in July 2014, covering the period of June 2013 to 8‐9 July 2014, resulted in 4242 records, of which we assessed 10 in full text. No new studies were included but we added three new excluded studies (<a href="./references#CD007989-bbs1-0002" title="">Excluded studies</a>). </p> <p>As far back as 2012, investigators indicated to us that they had heard that a plan for a randomised controlled trial of a newer medication (triptorelin), a GnRH agonist, was being proposed by Peer Briken and colleagues, but our investigations of the same bore no fruit. Early in 2014 we identified a study protocol for this trial (<a href="./references#CD007989-bbs2-0058" title="BrikenP , BernerW . Double‐blind, controlled, clinical trial planned in Germany to investigate the efficacy of psychotherapy combined with triptorelin in adult male patients with severe pedophilic disorders: presentation of the study protocol. Israel Journal of Psychiatry and Related Sciences2012;49(4):306‐13. ">Briken 2012</a>), whilst the reference remained 'in process' within MEDLINE. We anticipate incorporating its results into the first update of this review. </p> </section> <section id="CD007989-sec-0077"> <h4 class="title">Included studies</h4> <section id="CD007989-sec-0078"> <h5 class="title">Design</h5> <p>All seven included studies were published between 1974 and 1993.</p> <p>All studies are described as randomised controlled trials. Four out of seven employed a cross‐over design (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>; <a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>; <a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>; <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>); three studies used a parallel design with no cross‐over (<a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a>; <a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>; <a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>). Two early studies conducted in the same setting used 'Williams squares' or 'Latin squares' as part of their design (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>; <a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>). </p> <p>Four trials used a single comparison (<a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a>; <a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>; <a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>; <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>), whilst the other three trials each involved three conditions or 'arms' (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>; <a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>; <a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>). </p> <p>No study used clustering or reported stratification or matching of participants by type of offence, age, or any other participant characteristic. </p> </section> <section id="CD007989-sec-0079"> <h5 class="title">Sample sizes</h5> <p>The total number of participants randomised in the seven included studies was 138. The number randomised to eligible arms within the studies was 123. The difference between the two figures can be accounted for by the subtraction of participants from one ineligible active treatment arm from each of two three‐armed trials, <a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a> (n = 10) and <a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a> (n = 5) (see also <a href="./references#CD007989-sec-0188" title="">Characteristics of included studies</a>). </p> <p>Overall sample sizes were small, varying from nine (<a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>) to 37 (<a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a>). No study included a reference to any power calculation for change within this population. </p> </section> <section id="CD007989-sec-0080"> <h5 class="title">Setting and recruitment</h5> <p><b>Location</b> </p> <p>All studies were conducted in high‐income countries, largely English speaking, whether in the UK (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>; <a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>), Canada (<a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a>; <a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>; <a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>; <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>), or Australia (<a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>). We identified no study conducted in the USA. This is in contrast to <a href="./references#CD007989-bbs2-0088" title="DennisJ , HubandN , KhanO , FerriterM , JonesH , PowneyM , et al. Psychological interventions for adults who have sexually offended or are at risk of offending. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD007507.pub2] ">Dennis 2012</a> (a companion review with data from over 1000 participants in trials assessing the effects of psychological interventions on sex offenders) where five of the 10 included studies were conducted in the USA. </p> <p>Two studies, conducted in England by the same team of researchers (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>; <a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>), recruited from within a high security psychiatric hospital. Investigators in all other studies recruited male sex offenders or those with paraphilias who were receiving outpatient treatment, the majority of whom had already committed offences or had reported 'anomalous urges' likely to result in contact with law enforcement agencies, or both. </p> <p>Participants in some studies volunteered themselves for treatment after serving time in prison for offences. Other studies, for example, <a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>, included a mix of referrals, including court referrals of participants awaiting trial but not yet convicted of offences; here, those who were offered treatment were told that <i>"compliance in no way implied a more lenient judicial outcome"</i> (p 460). Participants who were already incarcerated were told that their participation would not influence their release from hospital, although if the drug were to be found effective, it might be helpful for them on their release (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>; <a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>). Hucker and colleagues recruited participants with a history of sex crimes against children, all of whom had been instructed to engage in some form of treatment as a condition of their probation (<a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>); these investigators made particular efforts to record baseline data on those offered treatment within their trial (n = 48) who declined to participate as well as data for those who consented. </p> </section> <section id="CD007989-sec-0081"> <h5 class="title">Participants</h5> <section id="CD007989-sec-0082"> <h6 class="title">Gender, age, and ethnicity</h6> <p>Whilst the capacity of women to commit sexual offences is recognised, the majority of sex offenders are male and all participants in the included studies were male. </p> <p>Participant age ranged from 16 to 68 years. Mean age varied from 26.08 (standard deviation (SD) = 3.87) (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>) to 43.11 (SD = 12.14) (<a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>). The largest study in the review (<a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a>, N = 37) included no data on age. </p> <p>Ethnicity of participants was not reported in any study.</p> </section> <section id="CD007989-sec-0083"> <h6 class="title">Baseline characteristics of participants</h6> <p>Participant characteristics in the seven included studies were heterogeneous, but were clearly reported in terms of offences committed, type of paraphilia (where relevant), and other details of the presenting clinical problem. </p> <p>Authors of the two British studies provided clear details of the time participants had spent in a secure hospital, their most recent offences (for example, from indecent exposure to rape to 'manslaughter with a sexual element') and the overall number of offences (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>; <a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>). Unsurprisingly, given their setting, these two trials included uniformly 'severe' offenders. </p> <p><a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a> included only those with a primary attraction to, and a history of offences against, children. <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a> included a 'mixed' group and reported on the nature of sexual deviation (for example, paedophilia and whether homosexual or heterosexual, and number of convictions). </p> <p>Investigators involved in the <a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a> study included, by comparison, less severe offenders (exhibitionists in the main, with some presenting with prominent voyeurism). The small study (n = 9) undertaken by Cooper et al provided sufficient details to make it clear that investigators had recruited two participants who would not meet the inclusion criteria for this review (hypersexuality and homosexuality but with no reported paedophilic interest) (<a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>). McConaghy et al described the offending behaviour and Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM‐III) (<a href="./references#CD007989-bbs2-0066" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐III). 3rd Edition. Washington, DC: American Psychiatric Association, 1980. ">APA 1980</a>) paraphilia status of participants in their study (<a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>), some of whom also might not meet contemporary criteria for offending. </p> <p>Other demographic information is reported well in only two studies. Data on IQ scores, education, alcohol, and drug use were reported in <a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>; data on marital status, literacy, IQ scores, brain damage, and mental illness (schizophrenia) were reported in <a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>. </p> <p>Overall (perhaps not surprisingly given the nature of the intervention), participants in studies included within this review were more likely to be in psychiatric care (within or outside the penal system) and more likely to have a diagnosis of a paraphilia than those in the companion review on psychological treatments for this population (<a href="./references#CD007989-bbs2-0088" title="DennisJ , HubandN , KhanO , FerriterM , JonesH , PowneyM , et al. Psychological interventions for adults who have sexually offended or are at risk of offending. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.CD007507.pub2] ">Dennis 2012</a>). </p> </section> <section id="CD007989-sec-0084"> <h6 class="title">Exclusion criteria</h6> <p>Four of the included trials did not report exclusion criteria. Exclusion criteria listed by <a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>, <a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>, and <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a> included having any medical conditions that would contraindicate participation, active psychosis, and an extensive list of medical and psychiatric conditions (from heart disease, cancer and sickle cell anaemia to severe depression), respectively. </p> </section> </section> <section id="CD007989-sec-0085"> <h5 class="title">Characteristics of interventions</h5> <p>Most interventions studied fell into the category of testosterone‐suppressing drugs involving progestogens or antiandrogens; only one small study assessed antipsychotics (<a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>). </p> <p><i>Testosterone‐suppressing drugs</i> </p> <p><a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a> compared ethinyl oestradiol (EO) with cyproterone acetate (CPA) (both testosterone‐suppressing drugs) versus placebo; <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a> and <a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a> compared cyproterone acetate (CPA) with placebo; <a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a> compared medroxyprogesterone acetate (MPA, delivered orally) with placebo; <a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a> compared medroxyprogesterone (MPA, intramuscular) with imaginal desensitisation versus imaginal desensitisation alone. <a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a> compared assertiveness training with MPA (orally) versus assertiveness training alone. </p> <p>We identified no study assessing the effects of serotonergic antidepressants (SSRIs) or gonadotropin‐releasing hormone (GnRH) analogues. </p> <section id="CD007989-sec-0086"> <h6 class="title">Trials of antilibidinal medications ('other')</h6> <p><a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a> compared benperidol with chlorpromazine (both antipsychotics) and placebo. </p> </section> </section> <section id="CD007989-sec-0087"> <h5 class="title">Outcomes</h5> <p><b>Sexual recidivism</b> <br/> Only two studies formally measured recividism by reports of being charged for sexual offences (<a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a>; <a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>). </p> <p>Two studies were both conducted in a high security facility from which participants were not due to be released for some years, if ever (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>; <a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>). Recividism data therefore could not be collected. Recividism data were also not reported in <a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>, where all participants undertook treatment as a condition of probation. </p> <p>In two studies, it was unclear whether "sexual activity" or "abnormal sexual activity" was of a criminal nature and therefore recividism cannot be said to be formally assessed (<a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>; <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>). </p> <p><b>Physiological capacity for sexual arousal</b> </p> <p>Capacity for sexual arousal was assessed by phallometric measures (for example, penile plethysmography or PPG); number of reported spontaneous erections; achieved orgasms; and circulating levels of hormones, including plasma testosterone. </p> <p><a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a> and <a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a> both used an overall "sexual activity score" derived from self reported data on the number of times that masturbation or "any overt sexual acts" led to orgasm; penile erection whilst watching erotic stimuli (film clips) was also measured in mm by means of a "mercury‐in‐rubber gauge" (<a href="./references#CD007989-bbs2-0072" title="BancroftJHJ , JonesHG , PullenBR . A simple transducer for measuring penile erection, with comments on its use in the treatment of sexual disorders. Behaviour Research and Therapy1966;4(3):239‐41. ">Bancroft 1966</a>; <a href="./references#CD007989-bbs2-0073" title="BancroftJHJ . The application of psychophysiological measures to the assessment and modification of sexual behaviour. Behaviour Research and Therapy1971;9(2):119‐30. ">Bancroft 1971</a>); the latter measure was also used by <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a> when assessing arousal in participants exposed to erotic stimuli during the course of a slideshow. </p> <p>Participants involved in three studies were asked to provide data on numbers of spontaneous erections, sexual outlets, and activity during the course of the trials (<a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>; <a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>; <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>). </p> <p>Physical capacity <i>per se</i> was not formally assessed in either <a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a> or <a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>. </p> <p><b>Sexually anomalous urges or sexual obsessions</b> </p> <p>These were measured variously as follows:</p> <p>The "sexual attitude score" (a "semantic differential technique" (<a href="./references#CD007989-bbs2-0135" title="MarksIM , SartoriusNH . A contribution to the measurement of sexual attitudes: the semantic differential as a measure of sexual attitude in sexual deviations. Journal of Nervous and Mental Diseases1967;145(6):441‐51. ">Marks 1967</a>)) uses four seven‐point scales. Here, a low number indicates positive interest and a high number indicates that the participant finds the stimulus "repulsive". This scale was the most common, used by investigators involved in two studies (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>; <a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>). </p> <p><a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a> reported self report scores of sexual interest; whilst, in another trial, frequency of sexual fantasies were subdivided into those about adults and those about children (<a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>). </p> <p>Data were collected on "sexually anomalous urges" as defined above by <a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>. </p> <p>Sexual arousal, as recorded by self report and rating scales in response to exposure to erotic stimuli via a slideshow, were recorded in one trial (<a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>). </p> <p><b>Anxiety</b> </p> <p>Anxiety was measured formally (<a href="./references#CD007989-bbs2-0162" title="SpielbergerCD . Manual for the State‐Trait Anxiety Inventory (STAI). Palo Alto, CA: Consulting Psychologists Press, 1983. ">Spielberger 1983</a>) in just one study (<a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>). "Feelings of anxiety" were measured (in an unvalidated way) in one study (<a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>). The 'calming' effects of interventions were reported anecdotally in two studies (<a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>; <a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>). </p> <p><b>Anger or aggression</b> </p> <p>Anger was measured formally in only one included study (<a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>), using the Buss‐Durkee Hostility Inventory (BDHI) (<a href="./references#CD007989-bbs2-0082" title="BussAH , DurkeeA . An inventory for assessing different kinds of hostility. Journal of Consulting and Clinical Psychology1957;21(4):343‐9. ">Buss 1957</a>). As above, the 'calming' effects of interventions were reported anecdotally in two studies (<a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>; <a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>). </p> <p><b>Dropping out of treatment</b> </p> <p>All included studies reported data on dropping out of treatment; all investigators reported reasons for the same. </p> <p><b>Adverse events</b> </p> <p>All included studies sought reports of adverse events.</p> </section> </section> <section id="CD007989-sec-0088"> <h4 class="title">Excluded studies</h4> <p>We formally excluded 50 studies from this review (reasons are given in the <a href="./references#CD007989-sec-0189" title="">Characteristics of excluded studies</a> table). Two relevant RCTs (one planned in Norway, the other in France) appear to have been terminated within the last decade (<a href="./references#CD007989-bbs2-0048" title="NøttestadJA . Cognitive and hormonal treatment of sex offenders. www.clinicaltrials.gov/show/NCT00379626 (accessed 7 June 2014). ">NCT00379626</a> and <a href="./references#CD007989-bbs2-0049" title="StolerauI . Comparison of two pharmacological treatments of pedophilia (PCNET). www.clinicaltrials.gov/show/NCT00601276 (accessed 7 June 2014). ">NCT00601276</a>, respectively). </p> </section> </section> <section id="CD007989-sec-0089"> <h3 class="title">Risk of bias in included studies</h3> <p>See also <a href="./references#CD007989-sec-0188" title="">Characteristics of included studies</a> and <a href="#CD007989-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD007989-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD007989-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007989.pub2/media/CDSR/CD007989/image_n/nCD007989-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <section id="CD007989-sec-0090"> <h4 class="title">Allocation</h4> <section id="CD007989-sec-0091"> <h5 class="title">Sequence generation</h5> <p>With the exception of <a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a> and <a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>, who used Williams square designs, no study authors described their methods of randomisation; however, personal communication with an author from <a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a> provided information that clarified the method of randomisation (<a href="./references#CD007989-bbs2-0078" title="BlaszczynskiA [pers comm] . Clarification of methods used in McConaghy 1983 and 1985 and confirmation that no data (means, standard deviations) remains on file. Reported that he knew of no other RCTs in the area [personal communication]. Email to: J Dennis 30‐31 August 2011. ">Blaszczynski 2011</a>), and in these three cases, we have assessed the risk of bias for this criterion to be low. In the four remaining cases, we judged the adequacy of sequence generation in the review to be unclear (even after communication with one author, <a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>). </p> </section> <section id="CD007989-sec-0092"> <h5 class="title">Allocation concealment</h5> <p>The method of allocation concealment was not reported in any study included within this review; however personal communications with one author, <a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>, caused us to reassess the risk of bias as low (as the investigator recalled remote assignment made by the pharmacist involved). In contrast, personal communication with an author involved in <a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a> led to an assessment of 'high' risk of bias for one study, as it was confirmed that no method of concealment was employed. We assessed the remaining five studies as unclear. </p> </section> </section> <section id="CD007989-sec-0093"> <h4 class="title">Blinding</h4> <section id="CD007989-sec-0094"> <h5 class="title">Participants and personnel</h5> <p>Care in blinding treating staff and participants by means of an off‐site pharmacist using coded bottles of identical intervention and placebo pills was clearly reported in the two oldest studies in the review (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>; <a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>); we therefore assessed these and <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a> (wherein staff are described as "blinded to allocation") as at low risk of bias. <a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a> reported using a placebo pill (described as "identical" to the active intervention), which would guarantee blinding of participants; we assessed the risk of bias of this study and of <a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a> within the context of this review as 'low'. </p> <p>We assessed <a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a> as being at high risk of bias as the conduct of one component of the intervention (imaginal desensitisation) could not be 'blinded' to anyone involved in the study. We assessed <a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a> as being at high risk of bias for the same reason (the intervention common to both arms of the trial was assertiveness training). </p> </section> <section id="CD007989-sec-0095"> <h5 class="title">Outcome assessors</h5> <p>We assessed three studies as having an overall low risk of bias given the measures taken to blind staff or assessors to group allocation (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>; <a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>; <a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>). </p> <p>We assessed two studies as having an unclear risk due to lack of information (<a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a>), or changes to study protocol based on participants being allowed to change treatment phase (<a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>). </p> <p>We rated the sixth study as having a high risk of bias as the measures of interest to this review were collected by self report only (<a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>). We also assessed the remaining study, <a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>, as having a high risk of bias (in contrast to previous work by the same authors, <a href="./references#CD007989-bbs2-0140" title="McConaghyN , ArmstrongMS , BlaszczynskiA . Expectancy, covert sensitization and imaginal desensitization in compulsive sexuality. Acta Psychiatrica Scandinavica1985;72(2):176‐87. ">McConaghy 1985</a>) because no attempt was made to blind outcome assessors. </p> </section> </section> <section id="CD007989-sec-0096"> <h4 class="title">Incomplete outcome data</h4> <p>Incomplete outcome data are a limitation in this review. In one study, <a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a> (n = 12), no data appeared to be missing (perhaps not surprising in a study of only 12 participants in a secure setting); however, it transpired that one that dropped out during the CPA phase was "replaced" by another participant. Within a similar study conducted in the same setting (<a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>), it is unclear which phases of the study saw the loss of three participants who withdrew or were withdrawn early in the study (for depression or other reasons). New participants were brought in to replace those that dropped out so that outcome data appear for 12 participants, but not those who were recruited. In <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>, we assessed the risk of bias as 'low' as reasons were supplied for the two participants who left (as well as details of their further conduct). </p> <p>Attempts to compensate for missing data appear to have been made in two studies, but with varying levels of clarity. In <a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>, the authors reported that to compensate for missing data, appropriate corrections were made, and analysis of variance carried out. For <a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>, a study in which a high level of dropout in the two drug intervention arms is reported (25% ‐ five of 20 ‐ did not complete their course of medication), the method of dealing with incomplete data is not given for all outcomes although results for all participants appear to be reported. </p> <p>We have assessed two studies as at 'high' risk of bias for this criterion (<a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a>; <a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>), given that the former featured a dropout rate of 67% in the combined treatment arm and 29% in that involving a psychological treatment alone. The study conducted by Hucker et al excluded data from one participant who had a 'medical condition' then lost a further four (almost 25% of the full sample) "of their own accord"; it transpired that these men had "higher frequency of fantasies about children" (p 234); the investigators themselves were unsure whether this might represent "selection bias" of a higher risk group unwilling or unable to give up fantasies about children (<a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>), thus leaving the remaining data at risk of bias. </p> </section> <section id="CD007989-sec-0097"> <h4 class="title">Selective reporting</h4> <p>Whilst we do not have access to any of the trial protocols for studies included within this review (which were largely conducted and reported in the 1970s and 1980s), we have identified no internal evidence of selective reporting in any paper, nor are any obvious outcomes missing. Testosterone data are missing from one study (<a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a>), but this may have been an artefact of measurement issues (data were described as "erratic"). Standard deviations are missing from some measures from another paper (<a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>), but there is no reason to suspect these were suppressed; data appear to have been lost (<a href="./references#CD007989-bbs2-0078" title="BlaszczynskiA [pers comm] . Clarification of methods used in McConaghy 1983 and 1985 and confirmation that no data (means, standard deviations) remains on file. Reported that he knew of no other RCTs in the area [personal communication]. Email to: J Dennis 30‐31 August 2011. ">Blaszczynski 2011</a>). </p> </section> <section id="CD007989-sec-0098"> <h4 class="title">Other potential sources of bias</h4> <p>Two potential sources of bias other than those recorded above have been identified. The first was beyond the control of all researchers conducting trials where treatments are not mandated, and that is the phenomenon of those unwilling to participate in treatment at all. Hucker et al remarked that <i>"a key question that is seldom addressed by researchers administering sex drive reducing drugs to sex offenders is the extent to which these drugs are accepted by patients"</i> (<a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>, p 229). As <i>"those participating in a treatment trial are already a select group...."</i> , Hucker et al emphasised the need for trialists to consider <i>"a count of all cases <b>approached</b>"</i> [emphasis added]. Such information was not always clear in the studies included within this review. In their own trial, Hucker et al noted that of 100 consecutively referred cases, only 48 were <i>"prepared to complete a comprehensive assessment, consider treatment, or even admit they might have a problem of sexual attraction toward children.... Of these 48, only 18 were willing to participate in a three month double blind trial of MPA versus placebo"</i> (p 231). </p> <p>In the trial conducted by Bradford and colleagues, authors admit in the discussion that <i>"the placebo phase in this study is not a truly inactive phase nor pharmacologically comparable to the baseline phase"</i> (p 396). </p> </section> </section> <section id="CD007989-sec-0099"> <h3 class="title" id="CD007989-sec-0099">Effects of interventions</h3> <p>We did not undertake meta‐analysis for reasons of heterogeneity of different types, which we summarise briefly here. </p> <p> <ul id="CD007989-list-0012"> <li> <p>Heterogeneity of interventions (results from different drug classes e.g., antilibidinals and antipsychotics must not be combined, as they have entirely different mechanisms of action, side effect profiles, etc.). Results of particular drugs within classes are not always comparable, e.g., ethinyl oestradiol (EO), cyproterone acetate (CPA), and medroxyprogesterone acetate (MPA) due to differing side effect profiles and other issues (the use of MPA is now virtually abandoned in many areas except as a female contraceptive). </p> </li> <li> <p>Even when interventions were identical, we had concerns regarding differing length of treatment regimes and carry‐over effects from cross‐over studies, especially between <a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a> (where CPA was administered in a 20‐week cross‐over trial with four‐week periods of prescription or four weeks' placebo) and <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>, where treatment lasted more than a year and was delivered in blocks of 12‐week prescription or 12‐week placebo, compromised (as the investigator admits) by participants being likely to have even more extended periods on the drug if they complained about intrusive thoughts) to the extent that the "placebo phase was not a true placebo phase" (<a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>). </p> </li> <li> <p>Difference in outcome measures or dropout rates or adequacy of data to calculate effect sizes. Whilst some trials are superficially similar (<a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a> and <a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a> feature MPA plus psychological treatment versus psychological treatment alone), the former trial reports few real data for analysis due to catastrophic dropout (100% of the MPA arm of the trial, 29% of the psychological treatment arm, and 67% of the combined treatment arm left the study). Finally, one might hope data from the latter trial, <a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>, might be comparable to data within the trial conducted by Hucker (<a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>), but the former provided no standard deviations (SDs) for any of the means provided for continuous data (and data have since been destroyed). These trials moreover have no dichotomous data (e.g., recividism) in common. </p> </li> </ul> </p> <p>Results are therefore reported narratively; first for antilibidinal medications involving testosterone‐suppressing drugs, then for 'other' antilibidinal medications. </p> <section id="CD007989-sec-0100"> <h4 class="title">1. Trials of antilibidinal medications involving antiandrogens (testosterone‐suppressing drugs) (six studies) </h4> <p>Six studies assessed the impact of testosterone‐suppressing drugs (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>; <a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a>; <a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>; <a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>; <a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>; <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>). </p> <section id="CD007989-sec-0101"> <h5 class="title">a) Ethinyl oestradiol to cyproterone acetate (both testosterone‐suppressing drugs) versus no treatment (one study) </h5> <p><a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a> reported on 12 patients within a high security institutional setting using a cross‐over design involving six‐week periods of no treatment, ethinyl oestradiol 0.01 mg (twice daily), and cyproterone acetate (CPA) 50 mg (twice daily). Investigators claim no carry‐over effects were evident in their analysis of residual effects, and concluded that <i>"there were no significant differences between the two drugs on any measure"</i> (p 312). </p> <p>For some outcomes, treatment was not superior to no treatment. Whilst "sexual attitudes" (deviant urges) appeared unaffected by treatment, physiological capacity could be affected. </p> <section id="CD007989-sec-0102"> <h6 class="title">Primary outcome</h6> <section id="CD007989-sec-0103"> <p><b>Sexual recidivism as measured by reconviction, self report, or caution</b></p> <p>Not reported within this study.</p> </section> </section> <section id="CD007989-sec-0104"> <h6 class="title">Secondary outcomes  </h6> <section id="CD007989-sec-0105"> <p><b>Physiological capacity for sexual arousal</b></p> <p>A "sexual activity score" was derived from data given by each participant on the number of times that masturbation or "any overt sexual acts" led to orgasm (p 310); penile erection whilst watching erotic stimuli (film clips) was also measured in millimetres by means of a "mercury‐in‐rubber gauge". For "sexual interest", means for all participants (n = 12) during the ethinyl oestradiol phase were 1.58 (SD = 0.84), compared with a mean of 1.67 (SD = 0.61) in the CPA phase, and a mean of 2.9 (SD = 0.89) in the no treatment phase (trial investigators' analysis: F = 9.44; df = 2.22; P value &lt; 0.001). Both drugs were reported to decrease sexual activity significantly in comparison with placebo. However, phallometric data (erectile responses to fantasy, slides, and film) did not demonstrate a statistically significant effect between treatments, with CPA only mildly superior to no treatment and ethinyl oestradiol not significantly different from no treatment. </p> </section> <section id="CD007989-sec-0106"> <p><b>Sexually anomalous urges or sexual obsessions</b></p> <p>The trial investigators report that <i>"When compared with no treatment... sexual attitudes were not significantly altered"</i> (p 312). During the ethinyl oestradiol phase, mean 'sexual attitude' scores were 9.68 (SD = 4.25), compared with a mean of 10.28 (SD = 5.25) in the CPA phase and 7.24 (SD = 3.49) in the no treatment phase (investigators' analysis: F = 1.91; df = 2.22; P value = not significant (NS)). </p> </section> <section id="CD007989-sec-0107"> <p><b>Anxiety; anger or aggression</b></p> <p>No data were reported for these outcomes.</p> </section> <section id="CD007989-sec-0108"> <p><b>Dropping out of treatment</b></p> <p>One participant was removed before completion of the study because of depression whilst in the CPA treatment phase. Trial investigators reported that his depression was unlikely to have been due to the treatment and that <i>"another patient . . . replaced"</i> him (p 313). </p> </section> <section id="CD007989-sec-0109"> <p><b>Adverse events, including suicide or suicide attempts, and sudden or unexpected death, from any cause</b></p> <p>No side effects attributable to the drugs were reported by the investigators. One participant was withdrawn three days after starting CPA having become depressed (see above) but this was not considered to be related to the intervention. </p> </section> </section> </section> <section id="CD007989-sec-0110"> <h5 class="title">b) Cyproterone acetate with placebo (two studies)</h5> <p><a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a> recruited 19 outpatients (volunteers) who fulfilled the Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised (DSM‐III‐R) criteria for paraphilia for at least 12 months, and had been charged with a related criminal offence (<a href="./references#CD007989-bbs2-0067" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐III‐R). 3rd Edition. Washington, DC: American Psychiatric Association, 1987. ">APA 1987</a>). The study used a cross‐over design with a one‐month baseline phase, followed by four three‐month periods of alternating cyproterone acetate (50 mg to 200 mg per day) or placebo for a total of 13 months. Investigators concluded that CPA was <i>"an effective agent when compared to placebo in controlling important aspects of sexual activity"</i> (<a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>, p 400), albeit with caveats concerning aspects of the cross‐over design employed. These included concerns about a potential <i>"rebound effect"</i> following the placebo phase of treatment, and the fact that some participants were moved on to the active phase of treatment if they experienced concerns about their own sexual impulses. </p> <p><a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>, in a community study, recruited nine participants. Seven of these men were described as presenting with severe sexual acting out resulting in social and legal implications, some of whom were facing trial. There is some concern that the remaining two participants might not meet the criteria for this review, as one was included on the basis of <i>"excessive demands on his wife"</i> (p 459) and the other was recruited due to homosexuality, without paedophilic interest. Participants were randomised in a cross‐over design as follows: no treatment, placebo, or cyproterone acetate 50 mg, twice daily; or no treatment, placebo, and then CPA, in four‐week phases. The trial investigators concluded that CPA was effective in reducing libido and associated sexual behaviour to <i>"acceptable levels"</i> (p 463). </p> <p>We judged meta‐analysis to be inappropriate because of differences in treatment length (treatment phases varied between four and 12 weeks), and inclusion criteria (Cooper's sample being demonstrably less 'severe' than Bradford's). A further limitation, acknowledged by the latter trial investigators, was that <i>"the placebo phase in this study is not a truly inactive phase nor pharmacologically comparable to the baseline phase"</i> (<a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>, p 396). This was related to the fact that inequalities in treatment dosage and duration will have been introduced in the Bradford study, as <i>"if the patient complained that sexual fantasies were returning or they were concerned they might reoffend they were moved ahead to the start of the next three month phase as it was possible that their complaints were due to placebo".</i> </p> <section id="CD007989-sec-0111"> <h6 class="title">Primary outcome</h6> <section id="CD007989-sec-0112"> <p><b>Sexual recidivism as measured by reconviction, self report, or caution</b></p> <p>In the study conducted by Bradford et al, recividism data are not reported specifically, although reference is made to two study participants who had apparently <i>"showed and reported excellent treatment responses to CPA"</i> (p 399) but dropped out because they felt they no longer required treatment. Within six months, one participant committed a "minor homosexual pedophilic act" for which he was charged (<a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>). One may infer no other charges took place during the course of the study, but this outcome does not appear to have been systematically assessed. </p> <p>Cooper et al do not describe asking about recidivism via self report when assessing sexual activity (recorded as a simple count of episodes rather than subdivided by type or character); therefore it is assumed no data are available for this outcome from this study (<a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>). </p> </section> </section> <section id="CD007989-sec-0113"> <h6 class="title">Secondary outcomes</h6> <section id="CD007989-sec-0114"> <p><b>Physiological capacity for sexual arousal</b></p> <p>Clinical measures for this outcome included monthly assessments of sex hormone profiles, penile tumescence (whilst watching erotic stimuli or contemplating a particular fantasy), sexual activity scores, counts of spontaneous daytime erections, and data from episodes of programmed masturbation. </p> <p>In terms of hormone profiles, measurement anomalies meant half of the prolactin data were unavailable for one study (<a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>). Luteinising hormone (LH) was not significantly affected across placebo and treatment phases but testosterone and follicle‐stimulating hormones (FSH) both changed significantly in the desired directions. Results of the other objective measure for arousal (millimetres of circumference change of the penis) were analysed as well as assessments by the subjective measure for this outcome (self report). Whilst arousal thus measured was significantly decreased between the baseline and active treatment stage, there were no statistically significant differences between placebo and treatment phases (all relevant data are reported as per the published paper, in <a href="#CD007989-tbl-0001">Table 1</a>). </p> <div class="table" id="CD007989-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Bradford 1993 data (Table III, pp 390‐1)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures or variable</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline x (SD)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo x (SD)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Active x (SD)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Wilks's F (df)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phase</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>t</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ENDOCRINE</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.81 (7.93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.52 (6.44)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.37 (6.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.46 d (2, 16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B ‐ A<br/> P ‐ A </p> <p>B ‐ P</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.52 <sup>d</sup> </p> <p>5.82 <sup>d</sup> </p> <p>0.70</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Luteinising hormone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.24 (4.81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.18 (5.15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.78 (5.22)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.854 (2, 14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follicle‐stimulating hormone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.78 (6.25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.42 (7.17)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.83 (5.37)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.37 b (2, 14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B ‐ A<br/> P ‐ A </p> <p>B ‐ P</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.71 <sup>c</sup> </p> <p>3.77 <sup>c</sup> </p> <p>‐78</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SEXUAL AROUSAL</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Slide (mm circ change)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.01 (8.77)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.07 (9.71)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.33 (9.54)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.33 (2, 16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fantasy (mm circ change)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.66 (7.23)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.25 (8.67)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.21 (7.87)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.75 (2, 16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Slide self report (mm circ change)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.29 (1.36)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.53 (1.81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.35 (1.62)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.68 a (2, 15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fantasy self report sexual arousal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.65 (1.47)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.41 (1.42)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.09 (1.68)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 (2, 15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PSYCHOPATHOLOGY</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPRS (total score)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.44 (5.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.33 (5.91)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.22 (4.59)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.48 d (2, 16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B ‐ A<br/> P ‐ A </p> <p>B ‐ P</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.96 <sup>d</sup> </p> <p>2.17 <sup>a</sup> </p> <p>3.21 <sup>c</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Buss‐Durkee Hostility Inventory</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.67 (10.43)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.50 (9.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.39 (9.11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SEXUAL BEHAVIOUR</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual interest</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.50 (1.09)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.94 (1.11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.78 (1.17)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.35 (2, 16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual activity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.65 (4.69)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.58 (8.25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.59 (4.19)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.91 d (2, 15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B ‐ A<br/> P ‐ A </p> <p>B ‐ P</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.56 <sup>a</sup> </p> <p>2.39 <sup>a</sup> </p> <p>‐0.49</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>B ‐ baseline<br/> A ‐ active<br/> P ‐ placebo<br/> BPRS ‐ Brief Psychiatric Rating Scale<br/> df ‐ degrees of freedom<br/> mm circ ‐ millimetres of circumference<br/> SD ‐ standard deviation<br/> <sup>a</sup>P value &lt; 0.005<br/> <sup>b</sup>P value &lt; 0.01<br/> <sup>c</sup>P value &lt; 0.005<br/> <sup>d</sup>P value &lt; 0.001 </p> </div> </div> <p>A statistically significant effect favouring treatment was found for the 'Sexual Activity Score' (calculated as the total number of orgasms reported for the week) (<a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>). This is correlated with data in another table provided by the investigators in which frequency of masturbation is significantly reduced by active treatment, but other forms of sexual activity (e.g., coitus and homosexual activity) show no difference. Sexual activity data are reproduced in <a href="#CD007989-tbl-0002">Table 2</a>. </p> <div class="table" id="CD007989-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Bradford 1993 (Table VII, Sexual activity, p 397)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Effect</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phase</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chi rank</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Friedmann 2‐way ANOVA Chi<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nocturnal emissions</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B<br/> A<br/> P </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.30</p> <p>1.77</p> <p>1.93</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2333 (df = 2)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spontaneous morning erections</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B<br/> A<br/> P </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.38</p> <p>1.66</p> <p>1.97</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1563 (df = 2)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spontaneous ejaculation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B<br/> A<br/> P </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.03</p> <p>1.88</p> <p>2.09</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4063 (df = 2)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Masturbation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B<br/> A<br/> P </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.47</p> <p>1.44</p> <p>2.09</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.7188 (df = 2, P value &lt; 0.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coitus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B<br/> A<br/> P </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.94</p> <p>2.09</p> <p>1.97</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2188 (df = 2)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Homosexual activity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B<br/> A<br/> P </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.91</p> <p>2.03</p> <p>2.06</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2188 (df = 2)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Homosexual change of partner</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B<br/> A<br/> P </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.91</p> <p>2.03</p> <p>2.06</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2188 (df = 2)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abnormal sexual activity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B<br/> A<br/> P </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.09</p> <p>2.03</p> <p>1.88</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4063 (df = 2)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>B ‐ baseline<br/> A ‐ active<br/> P ‐ placebo<br/> df ‐ degrees of freedom<br/> n ‐ number of participants </p> <p>Non‐significant effects except otherwise indicated.</p> </div> </div> <p><a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a> assessed spontaneous daytime erections and sexual outlets as well as arousal or pleasure during (programmed) masturbation. Results for CPA when compared with either no treatment or placebo were significant for both comparisons, even when strict significance levels were applied (P value &lt; 0.001). Here, the advantage for CPA over the other groups was 0.32, 0.17, and 13.2 respectively (<a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>). Investigators also sought confirmation that CPA was at a <i>"therapeutically adequate level"</i> by measuring testosterone plasma levels, commenting that their parallel reduction <i>"in the order of 30%"</i> (alongside those of troublesome sexual symptoms) was, although statistically highly significant, <i>"less important functionally"</i> , being<i>"secondary to suppression of hypothalamic releasing factors and pituitary gonadotrophins"</i> (p 463). The investigator also noted that oligospermia (reduction in volume of ejaculate) was remarked upon by all participants during the CPA phase (p 463). </p> </section> <section id="CD007989-sec-0115"> <p><b>Sexually anomalous urges or sexual obsessions</b></p> <p>"Sexual fantasies" were measured in <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>, where a statistically significant difference was found between baseline and both active and placebo phases, with fewer fantasies during the active phase; however, differences were not significant between active and placebo phases (<a href="#CD007989-tbl-0001">Table 1</a>). </p> <p><a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a> assessed sexual interest, defined as the level of intensity of thoughts and fantasies (i.e., whether <i>"mildly disturbing"</i> or <i>"highly disturbing"</i>) reported by participants on a scale from 0 to 100. CPA is significantly superior to no treatment for this outcome. </p> </section> <section id="CD007989-sec-0116"> <p><b>Anxiety</b></p> <p>Anxiety data were not specifically collected and reported in <a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>, but investigators note a <i>"dramatic anti aggressive effect"</i> (<a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>, p 463) similar to that reported in the literature, so providing evidence of <i>"the tranquillising actions"</i> of CPA (<a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>, p 463). </p> </section> <section id="CD007989-sec-0117"> <p><b>Anger or aggression</b></p> <p><a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a> assessed the effects of CPA on hostility as measured by the Buss‐Durkee Hostility Inventory (BDHI) and found "no differences" across any phase (run‐up or during either cross‐over period); however, the investigator noted that no participant met the clinical cut‐off point (38) at any phase. </p> <p><a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a> did not measure anger formally, but reported that<i>"the majority of patients noted that they were less irritable, more tolerant, and more relaxed physically and mentally"</i> during administration of CPA (p 463). </p> </section> <section id="CD007989-sec-0118"> <p><b>Dropping out of treatment</b></p> <p>Two participants (of 19) dropped out of <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>, including one man described as a homosexual paedophile and one sexually aggressive man with fantasies and urges to rape, both of whom were described as having<i>"reported excellent treatment responses to CPA"</i> (p 399) and left the study early as they felt they no longer needed treatment. The first participant was charged with a "minor" homosexual paedophilic act (fondling) three to six months afterwards and the second reported a return of fantasies six months later but he felt these could be controlled if his drinking was controlled too. </p> <p>No participants appeared to have left the study conducted by Cooper et al (<a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>). </p> </section> <section id="CD007989-sec-0119"> <p><b>Adverse events, including suicide or suicide attempts, and sudden or unexpected death, from any cause</b></p> <p>No statistically significant differences are reported in <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a> concerning general condition (physical, affective, concentration, social adjustment), mood measures (restlessness, anxiety, mood swings, loss of drive, suicide, euphoria) or somatic conditions (appetite, sleep, micturition, defecation, hair on head or body, flushes, sweating, headaches, nausea or vomiting, lumbago, gynaecomastia) between the various conditions for the duration of the study. Weight gain, however, was assessed as important with participants gaining an average of 3.1 kg throughout the duration of the trial. </p> <p>In contrast, <a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>, in a trial of shorter duration, reported that four of nine participants experienced <i>"some loss of energy"</i> (p 463). </p> </section> </section> </section> <section id="CD007989-sec-0120"> <h5 class="title">c) Medroxyprogesterone plus imaginal desensitisation versus imaginal desensitisation alone (one study) </h5> <p>One small study randomised 30 sex offenders to one of three treatments: medroxyprogesterone (via intramuscular injection, 150 mg, at fortnightly intervals for four injections, followed by four further injections at monthly intervals) versus imaginal desensitisation delivered over five days whilst admitted to a psychiatric hospital) versus combination medroxyprogesterone with imaginal desensitisation (<a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>). The trial investigators concluded that there were no significant differences in response to the three treatments. </p> <p>The investigators were principally interested in anxiety as an outcome (measured by the State‐Trait Anxiety Inventory (<a href="./references#CD007989-bbs2-0162" title="SpielbergerCD . Manual for the State‐Trait Anxiety Inventory (STAI). Palo Alto, CA: Consulting Psychologists Press, 1983. ">Spielberger 1983</a>)), as the hypothesis being tested in the trial was that <i>"compulsive sexual behaviours ... are driven by a sense of tension and excitement that becomes aversive if the patient doesn't complete the behaviour in situations where he feels the impulse to do so"</i> (p 200). Testosterone levels were also measured to check the effectiveness of medroxyprogesterone and the one‐month percentage of pre‐treatment levels shown to correlate with self‐ and assessor‐reported reductions in anomalous urges ‐ which was apparently also the case for levels of dihydrotestosterone, luteinising hormone, follicle‐stimulating hormone, and prolactin. Results of the two arms (n = 20) comparing medroxyprogesterone (MPA) with imaginal desensitisation, were as follows: </p> <section id="CD007989-sec-0121"> <h6 class="title">Primary outcome</h6> <section id="CD007989-sec-0122"> <p><b>Sexual recidivism as measured by reconviction, self report, or caution</b></p> <p>Recidivism data are reported using information obtained from solicitors or third party requests to clinicians on participants who had been formally charged for "sexually anomalous behaviour". At two‐year follow‐up, investigators found that no participant who had received both imaginal desensitisation and medroxyprogesterone had received a charge for sexually anomalous behaviour, whereas one who was treated with imaginal desensitisation alone relapsed. </p> </section> </section> <section id="CD007989-sec-0123"> <h6 class="title">Secondary outcomes</h6> <section id="CD007989-sec-0124"> <p><b>Physiological capacity for sexual arousal</b></p> <p>A number of hormone levels were checked in participants taking MPA within this trial, but only those for testosterone are reported. </p> <p>Testosterone levels were reported for both the combined treatment (MPA plus imaginal desensitisation) arm of this trial and for the MPA‐only condition (not reported on in this review). Of the 20 participants in these groups, testosterone was reduced from 6% to 63% of baseline levels (mean change 31%; range 0.92 to 15.1 nmol/l) (pp 201‐2). Correlations between <i>all</i> participants' testosterone levels at one‐month follow‐up and their anxiety levels as measured by the State‐Trait Anxiety Inventory (<a href="./references#CD007989-bbs2-0162" title="SpielbergerCD . Manual for the State‐Trait Anxiety Inventory (STAI). Palo Alto, CA: Consulting Psychologists Press, 1983. ">Spielberger 1983</a>) are also provided and effects are significant at a level of P value &lt; 0.01 at one month and one year for self assessed "anomalous urges". These results are, however, less robust when assessed by clinicians, particularly when "urge" is contrasted with "behaviour". </p> <p>Investigators also reported that <i>"most treated with</i> [the drug]<i>maintained heterosexual intercourse at pretreatment frequency"</i> (p 199). </p> </section> <section id="CD007989-sec-0125"> <p><b>Sexually anomalous urges or sexual obsessions</b></p> <p>Investigators summarised data on participant reports' of percentage reductions in "anomalous urges". Percentages are given without standard deviations and are reported narratively here. There was an average decrease in self reported anomalous urges of 70% at one month for the combined treatment group (medication plus imaginal desensitisation, n = 10), which improved further at one‐year follow‐up (75%). Decrease in self reported anomalous urges for the imaginal desensitisation‐only group (n = 10) was initially reduced at 52%, but approached levels reported by the combined‐group at one year, with the imaginal desensitisation‐only group reporting a 72% reduction in urges. </p> <p>The authors reported that of those who described complete control following treatment were discharged at one year. Of the 24 patients that met this criteria, three "relapsed" with anomalous behaviour; two of these had been treated with MPA alone and one with imaginal desensitisation alone. However, the authors reported that all three 'responded' to institution of MPA. </p> </section> <section id="CD007989-sec-0126"> <p><b>Anxiety</b></p> <p>Correlations between anxiety and testosterone are reported above (and these are the only data given by the treatment group). </p> <p>Investigators collected data for anxiety using the State‐Trait Anxiety Inventory (<a href="./references#CD007989-bbs2-0162" title="SpielbergerCD . Manual for the State‐Trait Anxiety Inventory (STAI). Palo Alto, CA: Consulting Psychologists Press, 1983. ">Spielberger 1983</a>) (both measures). Means were not provided by the treatment group and were further reported without either standard deviations (SDs) or precise P values. Personal contact with investigators revealed such data have not been preserved (<a href="./references#CD007989-bbs2-0078" title="BlaszczynskiA [pers comm] . Clarification of methods used in McConaghy 1983 and 1985 and confirmation that no data (means, standard deviations) remains on file. Reported that he knew of no other RCTs in the area [personal communication]. Email to: J Dennis 30‐31 August 2011. ">Blaszczynski 2011</a>). Investigators did report that "Patients STAI state and anxiety scores were significantly lower following than preceding all 3 treatments" (<a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>, p 202) and data in one table show group improvements between P value &lt; 0.001 for state anxiety at one year and P value &lt; 0.05 for trait anxiety at one year for all treated groups. </p> </section> <section id="CD007989-sec-0127"> <p><b>Anger or aggression</b></p> <p>No data are reported for this outcome.</p> </section> <section id="CD007989-sec-0128"> <p><b>Dropping out of treatment</b></p> <p>One participant allocated to combined treatment was <i>"concerned about his low level of normal sexual interest</i> [and] <i>decided not to have</i> [drug] <i>treatment when informed his plasma testosterone was low. He was treated with ID alone and excluded from the study"</i> (p 200). </p> </section> <section id="CD007989-sec-0129"> <p><b>Adverse events, including suicide or suicide attempts, and sudden or unexpected death, from any cause</b></p> <p>No adverse events were reported in the imaginal desensitisation alone group. Adverse events of the drug treatment (medroxyprogesterone) were reported in both the other treatment arms. Four participants ceased injections after three to five episodes due to side effects, though none were reported as having relapsed and they also <i>"reported persistence of the therapeutic effect"</i> (<a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>, p 201). One patient left the study (from the arm not included in this review) after five injections and did not maintain contact. </p> </section> </section> </section> <section id="CD007989-sec-0130"> <h5 class="title">d) Medroxyprogesterone acetate (MPA) versus placebo (one study)</h5> <p>One small study randomised 18 sex offenders with a primary attraction to children to either medroxyprogesterone acetate (orally) 200 mg daily or an identical placebo (<a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>). Investigators concluded that MPA was a <i>"useful sex drive reducing medication with few side effects"</i> (p 228) but that compliance was a major obstacle in this population. </p> <section id="CD007989-sec-0131"> <h6 class="title">Primary outcomes</h6> <section id="CD007989-sec-0132"> <p><b>Sexual recidivism as measured by reconviction, self report, or caution</b></p> <p>No formal data are reported for this outcome.</p> </section> </section> <section id="CD007989-sec-0133"> <h6 class="title">Secondary outcomes</h6> <section id="CD007989-sec-0134"> <p><b>Physiological capacity for sexual arousal</b></p> <p>Participants were asked to keep records of episodes of masturbation, intercourse, and total orgasms, as well as any change in frequency of orgasm, level or number of erections, and ejaculate volume on an "urges questionnaire". Investigators supplied only means (without SDs) and there appeared to be a substantial difference at baseline between the two small groups (placebo n = 6; treatment = 5). Whilst all urges appeared to decrease over the period of the study, there were no significant differences on the items listed above between groups. The trial investigators suggested that the overall decrease may have been a <i>"placebo effect of therapy itself or a systematic reduction in sexual activity of these individuals, perhaps due to incarceration"</i> (all participants were on probation) <i>"or some other non‐specific factors"</i> (p 235). Data are reproduced in <a href="#CD007989-tbl-0003">Table 3</a>. </p> <div class="table" id="CD007989-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Hucker 1988 data (Table 3, p 235)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo (n = 6)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo (n = 6)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MPA (n = 5)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MPA (n = 5)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FREQUENCY OF:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pre</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Post</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pre</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Post</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual fantasies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Masturbation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intercourse</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total orgasms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CHANGES IN:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frequency of orgasm</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Level of erection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of erections</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ejaculate volume</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>MPA ‐ medroxyprogesterone acetate</p> </div> </div> <p>The effect of MPA on sex hormones, metabolites, and liver enzymes was also reported within this trial. As with the data described above, there would seem to be substantial imbalances at baseline. Investigators reported significance levels for luteinising hormone (LH), follicle‐stimulating hormone (FSH), and testosterone, and reported that for <i>"FSH there is a main effect of drug condition but no interaction with time, F = 7.18, df = 1.14, P &lt; 0.05 as well as for LH, F = 6.60, df =1.14, P &lt; 0.05"</i> (<a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>, p 238). For testosterone, the drug effect was reported as <i>"F = 27.08, df = 1.14, P &lt; 0.01, and drug by time interaction F = 9.43, df = 1.53, P &lt; 0.01"</i> (p 238). </p> </section> <section id="CD007989-sec-0135"> <p><b>Sexually anomalous urges or sexual obsessions</b></p> <p>Investigators reported data on frequency of sexual thoughts and fantasies as part of the "urges questionnaire" mentioned above and these were the only results showing a significant time effect of MPA (SDs not given). The mean number of fantasies was 5.8 (n = 5) for the MPA group and 8.7 (n = 6) for the control group. </p> </section> <section id="CD007989-sec-0136"> <p><b>Anxiety; anger or aggression</b></p> <p>Data were not systematically reported but the investigators commented (p 240) that levels of anxiety and depression seemed high in the study, possibly due to participants' low mood as their court appearance approached, as well as due to other issues common amongst paedophiles, including alcohol and drug abuse. </p> </section> <section id="CD007989-sec-0137"> <p><b>Dropping out of treatment</b></p> <p>One participant allocated to treatment dropped out of the placebo phase due to the discovery of a thyroid tumour (unconnected to this study). A further four dropped out <i>"of their own accord"</i> (p 240). These men appeared to have had <i>"higher frequency of fantasies about children"</i> (p 234); the trial investigators themselves were unsure whether this might represent selection bias of a higher‐risk group unwilling or unable to give up fantasies about children. </p> </section> <section id="CD007989-sec-0138"> <p><b>Adverse events, including suicide or suicide attempts, and sudden or unexpected death, from any cause</b></p> <p>Two of 27 potential side effects were found to be statistically significant (depression and excess salivation). Participants in the placebo group complained of many symptoms and investigators suggested the likelihood of <i>"a complex interaction of awaiting trial, life circumstances and the MPA"</i> (p 235). Overall, investigators viewed "compliance in taking the drug as a major obstacle in its use with pedophiles" (p 228, <a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>). </p> </section> </section> </section> <section id="CD007989-sec-0139"> <h5 class="title">e) Assertiveness training with medroxyprogesterone acetate (MPA) versus assertiveness training alone (one study) </h5> <p>The largest study in this review randomised 37 men charged with exposure to either medroxyprogesterone acetate (MPA, aka Provera®) almost certainly delivered orally (100 to 150 mg daily) with assertiveness training involving 15 x one‐hour sessions of communication‐based training and with a third treatment group involving both MPA and assertiveness training (<a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a>). The latter therapy focused on communication with females but also addressed interpersonal difficulties and was tailored to individuals' own problems. All participants in the first group (MPA) discontinued almost immediately and analysis was confined to the two remaining groups, which also suffered substantial dropout (67% of the combined group and 29% of the assertiveness training group). Investigators concluded that MPA was associated with increased dropout and that side effects were substantial; participants were also more likely to leave assertiveness training if led by a female therapist. Recidivism data were compromised by the high rate of discontinuation. </p> <section id="CD007989-sec-0140"> <h6 class="title">Primary outcome</h6> <section id="CD007989-sec-0141"> <p><b>Sexual recidivism as measured by reconviction, self report, or caution</b></p> <p>We judged the results for this outcome to be at high risk of bias given the significant dropout rate (see below). By the end of the study, half (6/12) of the participants remaining in the assertiveness‐only treatment group and 20% (1/5) of participants remaining in the combined assertiveness training and MPA group recidivated. Participants who dropped out did so even though treatment had been mandated by the court. </p> </section> </section> <section id="CD007989-sec-0142"> <h6 class="title">Secondary outcomes</h6> <section id="CD007989-sec-0143"> <p><b>Physiological capacity for sexual arousal</b></p> <p>No data were reported for this outcome.</p> </section> <section id="CD007989-sec-0144"> <p><b>Sexually anomalous urges or sexual obsessions</b></p> <p>The investigators reported that by the end of treatment only three participants, or 9% of the total sample, experienced decreased urges to expose, but it is unclear how this was measured, and these results apply only to the subset of participants remaining in the study. </p> </section> <section id="CD007989-sec-0145"> <p><b>Anxiety; anger or aggression</b></p> <p>No data were reported for these outcomes.</p> </section> <section id="CD007989-sec-0146"> <p><b>Dropping out of treatment</b></p> <p>The entire medication‐only group (n = 5) discontinued treatment soon after the study commenced. Of the remaining 32 participants (17 in the combined group and 15 in the assertiveness training group), 47% dropped out of treatment before the full course was completed, leaving 12 in the assertiveness training group and five in the combined assertiveness training/MPA group. </p> </section> <section id="CD007989-sec-0147"> <p><b>Adverse events, including suicide or suicide attempts, and sudden or unexpected death, from any cause</b></p> <p>The investigators noted that <i>"Only two patients reported any side effects"</i> (p 279); these were weight gain and nausea (with the latter resolved by taking the medication with milk). Several participants reported feeling psychologically <i>"demasculated"</i> and this (the investigators suggest) <i>"may have been important in their dropping out of treatment".</i> (p 279). </p> </section> </section> </section> </section> <section id="CD007989-sec-0148"> <h4 class="title">2. Trials of antilibidinal medications ('other')</h4> <section id="CD007989-sec-0149"> <h5 class="title">Antipsychotics (benperidol and chlorpromazine) versus placebo (one study)</h5> <p>One small study (n = 12) compared two antipsychotics (benperidol and chlorpromazine) against placebo over 18 weeks (three six‐week periods) within a highly secure institutional setting (<a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>). Carry‐over effects were not investigated directly, although an unplanned, no treatment phase (which occurred when the active interventions were changed from syrup to tablet forms) allowed additional data to be collected. Based on these data, the investigators claimed that a placebo effect in this study was unlikely; they concluded that chlorpromazine was not effective whereas benperidol<i>"does have a libido reducing effect"</i> but this <i>"is weak and has only been convincingly demonstrated in terms of the reported frequency of sexual thoughts"</i> (p 270). </p> <section id="CD007989-sec-0150"> <h6 class="title">Primary outcome</h6> <section id="CD007989-sec-0151"> <p><b>Sexual recidivism as measured by reconviction, self report, or caution</b></p> <p>Not reported within this study.</p> </section> </section> <section id="CD007989-sec-0152"> <h6 class="title">Secondary outcomes  </h6> <section id="CD007989-sec-0153"> <p><b>Physiological capacity for sexual arousal</b></p> <p>The mean "sexual activity" score during the chlorpromazine phase was 3.17, compared with 1.33 in the benperidol phase, and 2.33 in the placebo phase (no SDs available; F = 2.5; df = 2.22; P value = non significant; investigators' analysis). Erections when viewing erotic slides or films were counted and there were no significant differences between conditions ((F &lt; 1.0) in both cases; investigators' analyses). </p> </section> <section id="CD007989-sec-0154"> <p><b>Sexually anomalous urges or sexual obsessions</b></p> <p>The mean score during the chlorpromazine phase for 'sexual attitude' (<a href="./references#CD007989-bbs2-0135" title="MarksIM , SartoriusNH . A contribution to the measurement of sexual attitudes: the semantic differential as a measure of sexual attitude in sexual deviations. Journal of Nervous and Mental Diseases1967;145(6):441‐51. ">Marks 1967</a>) was 7.09, compared with 9.99 in the benperidol phase, and 8.76 in the placebo phase (no SDs available; F = 5.1; df = 2.22; P value = 0.025; investigators' analysis). This represents a statistically significant difference between treatments in favour of benperidol over chlorpromazine, although neither was significantly better than placebo. </p> </section> <section id="CD007989-sec-0155"> <p><b>Anxiety; anger or aggression</b></p> <p>No data were reported for these outcomes.</p> </section> <section id="CD007989-sec-0156"> <p><b>Dropping out of treatment</b></p> <p>Three participants left the study early (two within the first week, of their own volition; a third was withdrawn due to severe depression). These three participants were replaced by three other volunteers. Subsequently, all participants appear to have remained in the study for its 18‐week duration. </p> </section> <section id="CD007989-sec-0157"> <p><b>Adverse events, including suicide or suicide attempts, and sudden or unexpected death, from any cause</b></p> <p>Data on side effects were measured throughout the study and whilst investigators noted that <i>"severity of side effects was not systematically assessed... patients' reports were recorded"</i> (p 270, <a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>), they also observed that, in some cases, side effects were of a severity <i>"either to present a transient marked disturbance or, if prolonged, to require increase in orphenadrine"</i> (to counteract extra‐pyramidal side effects). Results appear to indicate that benperidol was associated with considerably more dyskinetic extra‐pyramidal side effects than chlorpromazine, but that chlorpromazine was slightly superior in terms of drowsiness. Blurred vision, photosensitivity, dry mouth, and impaired exercise tolerance were also reported for both drugs. </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007989-sec-0158" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007989-sec-0158"></div> <section id="CD007989-sec-0159"> <h3 class="title" id="CD007989-sec-0159">Summary of main results</h3> <p>We identified seven studies that met our criteria for inclusion. No meta‐analysis was possible and all results were reported narratively. Five different drugs were used, two of which were in 'head‐to‐head' (active treatment comparison) trials (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>; <a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>); three against placebo alone (<a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>; <a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>; <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>); and two where the drug was augmented with a psychological intervention and compared against the psychological intervention on its own (<a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a>; <a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>). Three of the drugs were progestogens or antiandrogens; two were antipsychotics. There were no data on the use of serotonergic antidepressants (SSRIs) or gonadotropin‐releasing hormone (GnRH) analogues. </p> <p>The overall number (N) of participants for whom data were available in this review is 123. For any one outcome, data are available for a maximum of 100 participants. Given this fact (and the issues of consent and compliance mentioned elsewhere in this review) all results must be interpreted with caution. </p> <section id="CD007989-sec-0160"> <h4 class="title">Primary outcome ‐ sexual recividism as measured by reconviction, self report, or caution</h4> <p>Results for CPA were moderately encouraging, with reductions in some targets (e.g., physiological arousal) but recividism data do not appear to have been formally collected (<a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>; <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>); follow‐up ran for up to 13 months. Medroxyprogesterone acetate MPA (intramuscular) appeared effective in the one trial assessing it (<a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>), with no reports of recividism at two‐year follow‐up. Another small trial of MPA delivered orally did not report on recividism formally, but it may be inferred that no charges were made during the course of the trial (<a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>). In contrast, results for one trial of oral MPA in combination with psychological treatment were discouraging ‐ all participants in the arm of the trial assessing drug treatment alone dropped out immediately and of those few remaining in a combined drug and psychological treatment condition, 20% recidivated. Participants who dropped out did so even though treatment had been mandated by the court (<a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a>). </p> <p>Two studies included within this review took place in one highly secure psychiatric facility where participants' chance of release into the community was low, so collection of recividism data was impossible (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>; <a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>). </p> </section> <section id="CD007989-sec-0161"> <h4 class="title">Secondary outcomes</h4> <section id="CD007989-sec-0162"> <h5 class="title">Physiological capacity for sexual arousal</h5> <p>In one small study comparing ethinyl oestradiol (EO) to cyproterone acetate (CPA), both drugs were assessed as significantly decreasing sexual activity compared to placebo, but these self report data were not confirmed by phallometric data (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>). </p> <p>CPA was assessed as effective in decreasing capacity for arousal, number of orgasms, and hormone levels (testosterone, luteinising hormone (LH), follicle‐stimulating hormone (FSH)), compared to placebo in two studies (<a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>; <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>). MPA was also reported to reduce circulating testosterone significantly in one trial in which the drug was administered intramuscularly (<a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>). These encouraging results were not replicated in a trial assessing MPA by oral administration (<a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>), either in terms of sex hormones or in counts of sexual activity (e.g., numbers of erections and orgasms), where treatment and control results did not differ significantly and investigators postulated a "placebo effect of therapy itself" (<a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>, p 235). In the one small study assessing antipsychotics within this review (<a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>), chlorpromazine was superior to benperidol in reducing "sexual activity"; but in terms of measures of participants' arousal during erotic stimuli, no significant differences between drugs (or placebo) could be detected. </p> <p><i>Sexually anomalous urges or obsessions</i> </p> <p>"Sexual attitudes" were not significantly altered by either drug (EO or CPA) investigated in one small included trial (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>). CPA was assessed as effective in decreasing sexual interest and the "disturbing" intensity of fantasies in one study (<a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>), but in the larger study assessing CPA findings were less encouraging (<a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>), as a significant improvement for this outcome was recorded from baseline to end‐point for both active and placebo conditions, but not between active and placebo conditions. "Anomalous urges" were reduced by the administration of MPA intramuscularly in one study (<a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>), with an average decrease of 70% at one month, which was strengthened to 75% at one year; these encouraging results were replicated in a trial assessing MPA by oral administration (<a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>), where MPA intervention delivered its sole significant treatment effect (on frequency of sexual thoughts and fantasies). Results from another trial, which assessed the effects of a combination of orally administered MPA and psychological treatment (<a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a>), indicated that few participants experienced a decrease in urges to expose themselves, but it is unclear how this was measured. </p> <p>The effects of antipsychotics were assessed in one study on only 12 participants (<a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>). Results indicated that chlorpromazine was ineffective and that benperidol had (at best) a weak libido‐reducing effect. </p> <p><i>Anxiety</i> </p> <p>Anxiety was formally measured in only one trial (<a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>), where treatment (MPA) significantly reduced anxiety levels, and was formally correlated with a decrease in testosterone levels as well. Other investigators, e.g., <a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>, commented extensively on the "calming" nature of antiandrogen treatments in general (particularly, CPA). </p> <p><i>Anger or aggression</i> </p> <p>Only one study formally measured anger and found no significant differences in a comparison between CPA and placebo (<a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>); other investigators, e.g., <a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>, commented on the known "anti‐aggressive" effects of CPA. </p> <p><i>Dropping out of treatment</i> </p> <p>Participants left studies early in five of the seven studies, and effects on overall participant numbers ranged from 3% to 54%. </p> <p>In the study comparing EO with CPA, one individual (non‐treatment related) from a total of 12 participants droppped out (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>). One participant left the MPA‐only condition of the trial conducted by McConaghy et al (n = 31), due to concerns about his low sexual interest (<a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>). In the trial conducted by Hucker et al, four participants (all of whom had a high frequency of fantasies about children) left the study. Investigators commented that it was possible that this represented selection bias of a higher‐risk group unwilling to surrender fantasies of children (<a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>). One quarter (3/12) of the participants of the one trial assessing the effects of antipsychotics left the study, two of their own volition and one because of depression (<a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>). The most severe dropout took place in the three‐armed study conducted by Langevin et al (n = 37) in which MPA, assertiveness training, and MPA combined with assertiveness training, were compared. All participants in the first group dropped out immediately, five left the assertiveness training condition and 10 left the combined treatment condition (<a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a>). </p> </section> <section id="CD007989-sec-0163"> <h5 class="title">Adverse events, including suicide or suicide attempts, and sudden or unexpected death, from any cause </h5> <p>Six studies provided information on adverse events (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>; <a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>; <a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a>; <a href="./references#CD007989-bbs2-0004" title="HuckerS [pers comm] . Requesting clarification on matters regarding your 1979 and 1988 trial publications [personal communication]. Email to: J Dennis 28 March 2012. HuckerS , LangevinR , BainJ . A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse: A Journal of Research and Treatment1988;1(2):227‐42. ">Hucker 1988</a>; <a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>; <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>). No study tested the effects of testosterone‐suppressing drugs beyond six to eight months and the cross‐over design of some studies leads to further uncertainty (given the 'rebound effect' of some hormonal treatments). Considerable weight gain was reported in two trials of oral MPA and CPA. Side effects of intramuscular MPA led to discontinuation in some participants after three to five injections (the nature of these side effects was not described). Notable increases in depression and excess salivation were reported in one trial of oral MPA. The most severe side effects (extra‐pyramidal movement disorders and drowsiness) were reported in a trial of antipsychotic medication (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>). No deaths and no suicide attempts were reported in any of the studies. The latter is important given the association between antilibidinal hormonal medication and mood changes (<a href="./references#CD007989-bbs2-0167" title="ThibautF , De LaBarraF , GordonH , CosynsP , BradfordJM , WFSBP Task Force on Sexual Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias. World Journal of Biological Psychiatry2010;11(4):604‐55. ">Thibaut 2010</a>; <a href="./references#CD007989-bbs2-0105" title="GoorenLJ . Ethical and medical considerations of androgen deprivation treatment of sex offenders. Journal of Clinical Endocrinology and Metabolism2011;96(12):3628‐37. ">Gooren 2011</a>), and there has been at least one case report of treatment failure and attempted suicide associated with GnRH use (<a href="./references#CD007989-bbs2-0022" title="BrikenP , HillA , BernerW . A relapse in pedophilic sex offending and subsequent suicide attempt during luteinizing hormone‐releasing hormone treatment. Journal of Clinical Psychiatry2004;65(10):1429. ">Briken 2004</a>). Where reported, no significant effect of medication on dropout was noted. </p> <p>In summary, there were few trials of a limited number of drugs and limited duration, the effect of which on our primary outcome of recidivism reduction was not compelling, particularly given a) acceptance of treatment; b) adherence to treatment; and c) the possibility of adverse events. </p> </section> </section> </section> <section id="CD007989-sec-0164"> <h3 class="title" id="CD007989-sec-0164">Overall completeness and applicability of evidence</h3> <p>The evidence that addressed our review question was very weak. Only seven studies met our entry criteria and most of these were small, with an average of fewer than 20 individuals at randomisation. </p> <p>An additional and surprising limitation was the absence of any contemporary studies; the most recent that met our inclusion criteria was published two decades ago (<a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>). As a consequence, several new promising drugs (e.g., SSRIs and GnRH analogues) have no good quality trial evidence to support their use. This neglect of an important area of clinical practice requires urgent attention. </p> <p>There are other limitations too. As expected, all studies were on male participants. The fact that there were no intervention studies on females represents additional evidence of the historical limitation of our inquiry as it does not address recent attention to female sexual offending (<a href="./references#CD007989-bbs2-0102" title="GannonRA , CortoniF (editors) . Female Sexual Offenders: Theory, Assessment and Treatment. Chichester: John Wiley &amp; Sons, 2010. ">Gannon 2010</a>). Of note, progestogens (<a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>), SSRIs, and antipsychotics have similar effects in reducing libido in both sexes. </p> <p>In as much as current practice recommends that complementary psychological interventions be employed alongside pharmacological agents (<a href="./references#CD007989-bbs2-0134" title="LöselF , SchmuckerM . The effectiveness of treatment for sexual offenders: a comprehensive meta‐analysis. Journal of Experimental Criminology2005;1(1):117‐46. ">Lösel 2005</a>; <a href="./references#CD007989-bbs2-0081" title="BrikenP , KafkaMP . Pharmacological treatment for paraphilic patients and sexual offenders. Current Opinion in Psychiatry2007;20(6):609‐13. ">Briken 2007</a>), another limitation is that this type of combined treatment was only examined in two studies (<a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>; <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>). </p> <p>Two important limitations arise from the seriousness of the offending history and the setting in which the interventions took place. Profiles for recividism for categories of sex offenders vary, for example, those guilty of intrafamilial sex abuse have the lowest rate and exhibitionists have the highest rate of recividism (<a href="./references#CD007989-bbs2-0158" title="SetoM , BarbareeH . Psychopathy, treatment behavior, and sex offender recidivism. Journal of Interpersonal Violence1999;14(12):1235‐48. ">Seto 1999</a>), and most included studies recruited a variety of offender types and levels of severity within those types. The two trials that recruited serious sexual offenders were both in high security hospitals in the UK. Inevitably, investigators could not report recidivism data, as the individuals treated were not released because of the serious nature of their offences together with the location of their detention. Conversely, the trials in non‐institutional settings suffered from the opposite limitation – namely, that many of those recruited exhibited sexual behaviour that was not sufficiently serious enough to warrant a custodial sentence. For instance, the largest study included within this review included only sexual exhibitionists (<a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a>). Similarly, the nature of the sexual offending in other studies was such that there was only "<i>…</i> a possibility of imprisonment" (<a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>, p 459) suggesting that the behaviours may not have been extreme. </p> <p>Currently, the majority of those convicted of serious sexual offences are detained in prison; yet none of the trials reported here took place in a prison setting. While prison samples contain individuals with sexual behaviour of sufficient seriousness to merit a custodial sentence, as their numbers are very much greater than those in secure hospital, they offer the opportunity of intervening close to the offender's release date thereby allowing for the collection of recidivism data. </p> <p>As current criminological thinking suggests that sexual offenders have versatile criminal careers so that their sexual offending is part of their general offending behaviour, there is an argument for including general recidivism as a secondary outcome. Indeed, Lösel and Schmucker found in their 2005 review of the literature that interventions for sexual offending had an equivalent effect in reducing non‐sexual offending (<a href="./references#CD007989-bbs2-0134" title="LöselF , SchmuckerM . The effectiveness of treatment for sexual offenders: a comprehensive meta‐analysis. Journal of Experimental Criminology2005;1(1):117‐46. ">Lösel 2005</a>). This, however, introduces a further caveat in interpreting the evidence of efficacy as some programmes designed to reduce sexual offending may reduce further violent behaviour but not further reduce sexual offending. For instance, whilst the psychologically based prison sex offender treatment programme (SOTP) in the UK was shown to reduce future violent and sex offending when analysed in combination, it failed to demonstrate a statistically significant reduction in sex offending alone (<a href="./references#CD007989-bbs2-0100" title="FriendshipC , MannRE , BeechAR . Evaluation of a national prison‐based treatment program for sex offenders in England and Wales. Journal of Interpersonal Violence2003;18(7):744‐59. ">Friendship 2003</a>). </p> <p>This is an important distinction as follow‐up studies show that while sexual offenders continue to commit a range of offences (including sexual offences), violent non‐sexual offenders rarely commit further sexual offences (<a href="./references#CD007989-bbs2-0079" title="BontaJ , HansonRK . Violent recidivism of men released from prison. Paper Presented at the 103rd Annual Convention of the American Psychological Association; New York; USA. Washington, DC: American Psychological Association, 1995. ">Bonta 1995</a>; <a href="./references#CD007989-bbs2-0090" title="DugganCF , HollinCR , HubandN , ClarkeM , McCarthyL , DaviesS . A comparison of mentally disordered male offenders with and without a sexual offence: their characteristics and outcome. Sex Offender Treatment2013;8(1):1‐8. ">Duggan 2013</a>). This suggests that sexual offenders require specific interventions to reduce their propensity to reoffend sexually and that generic violence reduction programmes are insufficient. </p> <p>This absence of good quality evidence places the practitioner in an unenviable position. One the one hand, clinical practice necessitates that decisions have to be made here and now with whatever evidence is available. As Lösel and Schmucker point out: <i>"... policymaking and practice cannot wait until an unrealistic goal standard evaluation study but must be informed about the results of <b>sub‐optimal, quasi‐experimental studies</b>"</i> ((emphasis added) <a href="./references#CD007989-bbs2-0133" title="LöselF , SchmuckerM . Protocol for a systematic review of the effects of sexual offender treatment. www.campbellcollaboration.org/lib/project/53/(accessed September 2014). ">Lösel 2003</a>, p 3). In the absence of good quality evidence from appropriate trials, clinicians have to resort to guidelines drawn from expert opinion such as those of Thibaut et al (2010) on the role of pharmacological agents for paraphilias (<a href="./references#CD007989-bbs2-0167" title="ThibautF , De LaBarraF , GordonH , CosynsP , BradfordJM , WFSBP Task Force on Sexual Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias. World Journal of Biological Psychiatry2010;11(4):604‐55. ">Thibaut 2010</a>). In so doing, it is surely important that quasi‐judicial hearings (e.g., the parole board) determining the release or further incarceration of a sexual offender, on the basis of whether he has engaged successfully with sex offending treatment, are properly informed as regards uncertainties about the evidence base for such treatment. </p> <p>In summary, while there are a number of serious ethical challenges in conducting trials in this area that we will consider further below, the fact remains that the evidence in support of any pharmacological intervention for those who sexually offend is very limited. </p> </section> <section id="CD007989-sec-0165"> <h3 class="title" id="CD007989-sec-0165">Quality of the evidence</h3> <p>Our review retrieved seven small studies with a total of 138 participants, for whom data were available for only 123. No study was preceded by a defined pre‐published protocol and each contained several methodological flaws. No study described attempts to conceal allocation, few could be considered to have adequate sequence generation (<a href="./references#CD007989-bbs2-0001" title="BancroftJ , TennettG , LoucasK , CassJ . The control of deviant sexual behaviour by drugs. 1. Behavioural changes following oestrogens and anti‐androgens. British Journal of Psychiatry1974;125(1):310‐5. ">Bancroft 1974</a>; <a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>), and blinding of outcome assessors was an issue in several. These limitations do not allow robust conclusions to be drawn. </p> <p>A significant issue was the cross‐over design used in most included studies, particularly as rebound hypersexuality may occur in placebo phases due to receptor hypersensitivity, and may take a month to normalise (<a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>). Given that medication treatment phases ranged from three to six months, the possibility of carry‐over effects should also be considered. </p> <p>Despite this, most studies consistently showed reductions in sexual interest and arousal with medication intervention, with three studies being able to correlate this to reduced plasma levels of testosterone (<a href="./references#CD007989-bbs2-0003" title="CooperAJ . A placebo‐controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry1981;22(5):458‐65. ">Cooper 1981</a>; <a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>; <a href="./references#CD007989-bbs2-0002" title="BradfordJMW , PawlakA . Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Archives of Sexual Behavior1993;22(6):629‐41. ">Bradford 1993</a>). </p> </section> <section id="CD007989-sec-0166"> <h3 class="title" id="CD007989-sec-0166">Potential biases in the review process</h3> <p>Meta‐analysis does suggest that deviant sexual interests and sexual preoccupation are significant predictors of sexual recidivism (<a href="./references#CD007989-bbs2-0115" title="HansonRK , Morton‐BourgonKE . The characteristics of persistent sexual offenders: a meta‐analysis of recidivism studies. Journal of Consulting and Clinical Psychology2005;73(6):1154‐63. ">Hanson 2005</a>). This is relevant as, except for the Tennent study (<a href="./references#CD007989-bbs2-0007" title="TennentG , BancroftJ , CassJ . The control of deviant sexual behavior by drugs: a double‐blind controlled study of benperidol, chlorpromazine, and placebo. Archives of Sexual Behaviour1974;3(3):261‐71. ">Tennent 1974</a>), which used typical neuroleptics, the other studies employing testosterone‐lowering interventions or oestrogens all showed a positive effect in reducing various components of the sexual process. Whether this translates in turn to a reduction of sexual reoffending has not been answered. </p> <p>Treatment for sexual offending may have positive consequences other than a reduction of further sexual offending, including non‐sexual offending and improved psychological health (<a href="./references#CD007989-bbs2-0111" title="HansenH , Lykke‐OlesenL . Treatment of dangerous sexual offenders in Denmark. Journal of Forensic Psychiatry1997;8(1):195‐9. ">Hansen 1997</a>), but these outcomes are not discussed in this review. These are important limitations as current criminological thinking suggests that sexual offenders have versatile criminal careers such that their sexual offending is part of their general offending behaviour (<a href="./references#CD007989-bbs2-0159" title="SimonLMJ , FelthousAR . Sex offenders: part two/three. Public policy. Behavioral Sciences &amp; the Law2000;18(2‐3):131‐4. ">Simon 2000</a>; <a href="./references#CD007989-bbs2-0116" title="HansonRK . Meta‐analysis of treatment outcome in sexual offenders. Oral Presentation of Paper at 11th Conference of the International Association for the Treatment of Sex Offenders in Oslo. 2010. ">Hanson 2010</a>), creating an argument for including general recidivism as a secondary outcome. Indeed, Lösel and Schmucker found in their 2005 review of the literature that interventions for sexual offending had an equivalent effect in reducing non‐sexual offending (<a href="./references#CD007989-bbs2-0134" title="LöselF , SchmuckerM . The effectiveness of treatment for sexual offenders: a comprehensive meta‐analysis. Journal of Experimental Criminology2005;1(1):117‐46. ">Lösel 2005</a>). Our failure to consider this issue therefore can be seen as a limitation; however, had we so done we would have been obliged to report that none of our included studies reported on non‐sexual offending. </p> <p>An additional limitation was our restriction to studies with a randomised design, which explains why our conclusions are discrepant with those of other reviews (e.g., <a href="./references#CD007989-bbs2-0134" title="LöselF , SchmuckerM . The effectiveness of treatment for sexual offenders: a comprehensive meta‐analysis. Journal of Experimental Criminology2005;1(1):117‐46. ">Lösel 2005</a>), which included evidence from non‐randomised trials. We recognise the importance of such trials; however, as they produce suggestive evidence of effectiveness that then needs to be trialled in rigorous randomised trials later, we effectively excluded other studies that might otherwise provide useful data. The current situation is therefore one in which some non‐randomised trials of poor quality can show a significant effect for medication while randomised trials that are of superior quality can only report weak evidence. </p> <p>One additional important bias that arises when one restricts the review to randomised controlled trials (RCTs) is that, as the process of recruitment requires informed consent, it is likely to result in only the most compliant being included, particularly for this type of treatment. <a href="./references#CD007989-bbs2-0145" title="Nagayama‐HallGC . Sexual offender recidivism revisited: a meta‐analysis of recent treatment studies. Journal of Consulting and Clinical Psychology1995;63(5):802‐9. ">Nagayama‐Hall 1995</a> pointed out that psychological treatment was considered acceptable by two‐thirds of offenders, but pharmacological treatment only by one‐third). Thus, failing to consider that only a minority of offenders will consent to treatment might inflate the effect of those trials of medication that show benefit. Consequently, it is difficult to generalise the findings from such trials to other sex offenders who might require (and possibly benefit from) such intervention, but who refuse to accept or comply with it. </p> </section> <section id="CD007989-sec-0167"> <h3 class="title" id="CD007989-sec-0167">Agreements and disagreements with other studies or reviews</h3> <p>This report was preceded by several major reviews into the treatment of sexual offending. These have arrived at mixed conclusions; some claiming that interventions are effective in reducing recidivism and others the reverse. </p> <p>Furby, Weinrott, and Blackshaw concluded that treatment did not reduce recidivism rates in sex offenders (<a href="./references#CD007989-bbs2-0101" title="FurbyL , WeinrottMR , BlackshawL . Sex offender recidivism: a review. Psychological Bulletin1989;105(1):3‐30. ">Furby 1989</a>). Nagayama‐Hall updated the Furby et al review by conducting a meta‐analysis of 12 new studies that contradicted its predecessor by finding equivalent positive effects for hormonal treatment and cognitive behavioural therapy (CBT), both of which were assessed as superior to behavioural interventions (<a href="./references#CD007989-bbs2-0145" title="Nagayama‐HallGC . Sexual offender recidivism revisited: a meta‐analysis of recent treatment studies. Journal of Consulting and Clinical Psychology1995;63(5):802‐9. ">Nagayama‐Hall 1995</a>). Overall, treatment was found to be modest in its effect, reducing recidivism by 8%. Castrated patients had the lowest recidivism rate (0.3) and the largest effect sizes (<i>r</i> = 0.53). An early Cochrane review by White et al identified only a single drug trial (i.e., MPA reviewed in this report) and found it to be ineffective (<a href="./references#CD007989-bbs2-0171" title="WhiteP , BradleyC , FerriterM , HatzipetrouL . Managements for people with disorders of sexual preference and for convicted sexual offenders. Cochrane Database of Systematic Reviews1998, Issue 4. [DOI: 10.1002/14651858.CD000251] ">White 1998</a>). </p> <p>Lösel and Schmucker conducted a thorough systematic review of controlled outcome studies of all relevant interventions, which included 80 comparisons involving data from 22,181 participants (<a href="./references#CD007989-bbs2-0134" title="LöselF , SchmuckerM . The effectiveness of treatment for sexual offenders: a comprehensive meta‐analysis. Journal of Experimental Criminology2005;1(1):117‐46. ">Lösel 2005</a>). This review included data from both published and unpublished studies reported up to June 2003. Main results featured a large effect size for surgical castration (odds ratio (OR) 15.34; 95% confidence interval (CI) 7.34 to 32.05; eight studies), and a reasonably large effect size for hormonal treatment (OR 3.08; 95% CI 1.40 to 6.79; six studies). This compared to a moderate effect size for CBT (OR 1.45; 95% CI 1.12 to 1.86; 35 studies). Overall, 11.1% of the treated offenders and 17.5% of the controls showed sexual recidivism (a 37% difference) when both pharmacological and psychological treatments were considered. The authors also noted that the interventions were effective in reducing reoffending in general. </p> <p>More recently, two relevant literature reviews have appeared focusing on drug treatments for both paraphilic and non‐paraphilic sexual disorders (<a href="./references#CD007989-bbs2-0109" title="GuayDR . Drug treatment of paraphiliac and nonparaphiliac sexual disorders. Clinical Therapeutics2009;31(1):1‐31. ">Guay 2009</a>) and for paraphilic disorders alone (<a href="./references#CD007989-bbs2-0103" title="GarciaFD , ThibautF . Current concepts in the pharmacotherapy of paraphilias. Drugs2011;71(6):771‐90. ">Garcia 2011</a>). Neither restricted itself to trials of any particular study design; neither searched more than two databases; both indicated that treatment looked promising but that the state of the intervention literature was poor. Subsequently, Langstrom and colleagues conducted a review of the effectiveness of treatments for offenders against children (<a href="./references#CD007989-bbs2-0128" title="LangstromN , EnebrinkP , LaurenE‐M , LindblomJ , WerkoS , HansonRK . Preventing sexual abusers of children from reoffending: systematic review of medical and psychological interventions. BMJ 2013 August 9 [Epub ahead of print]. ">Langstrom 2013</a>). These authors did not restrict their review by type of treatment, by age of offender, or to randomised controlled trials. Their review included eight studies and the authors did not find meta‐analysis feasible. Conclusions were that scientific evidence is weak and that there is an urgent need for better quality studies. </p> <p>One explanation for these discrepant findings is that the quality of the evidence required to arrive at a conclusion differed. This variability arises from differences in the types of study design. Indeed, a similar point was made by Rice and Harris (<a href="./references#CD007989-bbs2-0154" title="RiceME , HarrisGT . The size and sign of treatment effects in sex offender therapy. Annals of the New York Academy of Sciences2003;989:428‐40; discussion 441‐5. ">Rice 2003</a>), when commenting on the previous review by Hanson and colleagues (<a href="./references#CD007989-bbs2-0114" title="HansonRK , GordonA , HarrisAJ , MarquesJK , MurphyW , QuinseyVL , et al. First report of the collaborative outcome data project on the effectiveness of psychological treatment for sex offenders. Sex Abuse2002;14(2):169‐94. ">Hanson 2002</a>). Rice and Harris observed that not only were many methodologically flawed studies included, but that the 'best' studies showed no effect. Similarly, the review by Lösel and Schmucker cast its net very widely, with 60% of the studies considered to be of non‐equivalent design (only six were RCTs) (<a href="./references#CD007989-bbs2-0134" title="LöselF , SchmuckerM . The effectiveness of treatment for sexual offenders: a comprehensive meta‐analysis. Journal of Experimental Criminology2005;1(1):117‐46. ">Lösel 2005</a>). Mindful of Sackett et al's 1996 warning that <i>"</i> …<i>we should avoid non‐experimental approaches … since these routinely lead to false positive conclusions about efficacy</i> …<i>"</i> (<a href="./references#CD007989-bbs2-0156" title="SackettDL , RosenbergWMC , GrayJAM , HaynesRB , RichardsonWS . Evidence based medicine: what it is and what it isn't. BMJ1996;312:71. ">Sackett 1996</a>, p 71), this raises concerns regarding the positive conclusions in relation to the efficacy of current interventions. Moreover, only two of the seven trials described in this report were considered in their meta‐analysis (<a href="./references#CD007989-bbs2-0005" title="LangevinR , PaitichD , HuckerS , NewmanS , RamsayG , PopeS , et al. The effect of assertiveness training, Provera and sex of therapist in the treatment of genital exhibitionism. Journal of Behavior Therapy and Experimental Psychiatry1979;10(4):275‐82. ">Langevin 1979</a>; <a href="./references#CD007989-bbs2-0006" title="McConaghyNBA , BlaszczynskiA , KidsonW . Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone. Acta Psychiatrica Scandinavica1988;77(2):199‐206. ">McConaghy 1988</a>), because their inclusion criteria specified recividism as a prospective outcome. To be fair to the authors, they do acknowledge that <i>"we need more high‐quality outcome studies that address specific subgroups of sex offenders as well as more detailed process evaluations on various treatment characteristics and components."</i> (<a href="./references#CD007989-bbs2-0134" title="LöselF , SchmuckerM . The effectiveness of treatment for sexual offenders: a comprehensive meta‐analysis. Journal of Experimental Criminology2005;1(1):117‐46. ">Lösel 2005</a>, p 138). Briken and Kafka concluded that, even after decades of experimentation, pharmacological treatments showed "definite promise" but further research was required and pharmacological treatment should not be seen as a "standalone" treatment (<a href="./references#CD007989-bbs2-0081" title="BrikenP , KafkaMP . Pharmacological treatment for paraphilic patients and sexual offenders. Current Opinion in Psychiatry2007;20(6):609‐13. ">Briken 2007</a>); Eher likewise deplored the quality of the existing evidence base (<a href="./references#CD007989-bbs2-0095" title="EherR . Antiandrogen treatment of sexual offenders: empirical evidence and criminological facts [Die antiandrogene behandlung von sexualstraftatern vor dem hintergrund der aktuellen wirksamkeitsforschung und der kriminologischen realitat]. Forensische Psychiatrie, Psychologie, Kriminologie2010;4(1):S27‐32. [DOI: 10.1007/s11757‐010‐0055‐6] ">Eher 2010</a>). The present review concurs in finding, as yet, no compelling evidence in favour of medication. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007989-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007989.pub2/media/CDSR/CD007989/urn:x-wiley:14651858:media:CD007989:CD007989-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007989.pub2/media/CDSR/CD007989/image_t/tCD007989-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="From Gelb 2007 (used with permission of the Sentencing Advisory Council, Melbourne, Victoria, Australia)" data-id="CD007989-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007989.pub2/media/CDSR/CD007989/image_n/nCD007989-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>From <a href="./references#CD007989-bbs2-0104" title="GelbK . Recividism of sex offenders research paper. http://goo.gl/uGmOrg (accessed 13 February 2014). ">Gelb 2007</a> (used with permission of the Sentencing Advisory Council, Melbourne, Victoria, Australia) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007989.pub2/full#CD007989-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007989.pub2/media/CDSR/CD007989/image_n/nCD007989-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007989-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007989.pub2/media/CDSR/CD007989/urn:x-wiley:14651858:media:CD007989:CD007989-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007989.pub2/media/CDSR/CD007989/image_t/tCD007989-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD007989-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007989.pub2/media/CDSR/CD007989/image_n/nCD007989-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007989.pub2/full#CD007989-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007989.pub2/media/CDSR/CD007989/image_n/nCD007989-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD007989-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Bradford 1993 data (Table III, pp 390‐1)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures or variable</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Baseline x (SD)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo x (SD)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Active x (SD)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Wilks's F (df)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phase</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>t</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ENDOCRINE</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Testosterone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.81 (7.93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.52 (6.44)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.37 (6.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.46 d (2, 16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B ‐ A<br/> P ‐ A </p> <p>B ‐ P</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.52 <sup>d</sup> </p> <p>5.82 <sup>d</sup> </p> <p>0.70</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Luteinising hormone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.24 (4.81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.18 (5.15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.78 (5.22)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.854 (2, 14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follicle‐stimulating hormone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.78 (6.25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.42 (7.17)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.83 (5.37)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.37 b (2, 14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B ‐ A<br/> P ‐ A </p> <p>B ‐ P</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.71 <sup>c</sup> </p> <p>3.77 <sup>c</sup> </p> <p>‐78</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SEXUAL AROUSAL</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Slide (mm circ change)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.01 (8.77)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.07 (9.71)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.33 (9.54)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.33 (2, 16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fantasy (mm circ change)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.66 (7.23)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.25 (8.67)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.21 (7.87)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.75 (2, 16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Slide self report (mm circ change)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.29 (1.36)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.53 (1.81)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.35 (1.62)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.68 a (2, 15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fantasy self report sexual arousal</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.65 (1.47)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.41 (1.42)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.09 (1.68)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 (2, 15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PSYCHOPATHOLOGY</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPRS (total score)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.44 (5.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.33 (5.91)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.22 (4.59)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.48 d (2, 16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B ‐ A<br/> P ‐ A </p> <p>B ‐ P</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.96 <sup>d</sup> </p> <p>2.17 <sup>a</sup> </p> <p>3.21 <sup>c</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Buss‐Durkee Hostility Inventory</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.67 (10.43)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.50 (9.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.39 (9.11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SEXUAL BEHAVIOUR</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual interest</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.50 (1.09)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.94 (1.11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.78 (1.17)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.35 (2, 16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual activity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.65 (4.69)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.58 (8.25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.59 (4.19)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.91 d (2, 15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B ‐ A<br/> P ‐ A </p> <p>B ‐ P</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.56 <sup>a</sup> </p> <p>2.39 <sup>a</sup> </p> <p>‐0.49</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>B ‐ baseline<br/> A ‐ active<br/> P ‐ placebo<br/> BPRS ‐ Brief Psychiatric Rating Scale<br/> df ‐ degrees of freedom<br/> mm circ ‐ millimetres of circumference<br/> SD ‐ standard deviation<br/> <sup>a</sup>P value &lt; 0.005<br/> <sup>b</sup>P value &lt; 0.01<br/> <sup>c</sup>P value &lt; 0.005<br/> <sup>d</sup>P value &lt; 0.001 </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Bradford 1993 data (Table III, pp 390‐1)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007989.pub2/full#CD007989-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007989-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Bradford 1993 (Table VII, Sexual activity, p 397)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Effect</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phase</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chi rank</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cases (n)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Friedmann 2‐way ANOVA Chi<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nocturnal emissions</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B<br/> A<br/> P </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.30</p> <p>1.77</p> <p>1.93</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2333 (df = 2)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spontaneous morning erections</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B<br/> A<br/> P </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.38</p> <p>1.66</p> <p>1.97</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1563 (df = 2)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spontaneous ejaculation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B<br/> A<br/> P </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.03</p> <p>1.88</p> <p>2.09</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4063 (df = 2)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Masturbation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B<br/> A<br/> P </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.47</p> <p>1.44</p> <p>2.09</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.7188 (df = 2, P value &lt; 0.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Coitus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B<br/> A<br/> P </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.94</p> <p>2.09</p> <p>1.97</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2188 (df = 2)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Homosexual activity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B<br/> A<br/> P </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.91</p> <p>2.03</p> <p>2.06</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2188 (df = 2)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Homosexual change of partner</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B<br/> A<br/> P </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.91</p> <p>2.03</p> <p>2.06</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2188 (df = 2)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abnormal sexual activity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>B<br/> A<br/> P </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.09</p> <p>2.03</p> <p>1.88</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4063 (df = 2)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>B ‐ baseline<br/> A ‐ active<br/> P ‐ placebo<br/> df ‐ degrees of freedom<br/> n ‐ number of participants </p> <p>Non‐significant effects except otherwise indicated.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Bradford 1993 (Table VII, Sexual activity, p 397)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007989.pub2/full#CD007989-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007989-tbl-0003"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Hucker 1988 data (Table 3, p 235)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo (n = 6)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo (n = 6)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MPA (n = 5)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MPA (n = 5)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FREQUENCY OF:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pre</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Post</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pre</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Post</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sexual fantasies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Masturbation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intercourse</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total orgasms</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CHANGES IN:</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frequency of orgasm</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Level of erection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of erections</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ejaculate volume</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>MPA ‐ medroxyprogesterone acetate</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Hucker 1988 data (Table 3, p 235)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007989.pub2/full#CD007989-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007989.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD007989-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD007989-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007989-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD007989-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD007989-note-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="pt#CD007989-note-0003">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD007989-note-0002">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007989\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007989\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007989\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007989\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007989\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007989\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007989\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007989\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007989\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007989\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007989\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007989\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007989\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007989\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007989\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007989\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007989\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007989\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tIsQXAzh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007989.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007989.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007989.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007989.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007989.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724573715"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007989.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724573719"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007989.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e66231903f44a',t:'MTc0MDcyNDU3NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 